Impact of protein supplementation on muscle recovery after exercise-induced muscle soreness by Dahlstrom, Elizabeth Carol
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2007
Impact of protein supplementation on muscle
recovery after exercise-induced muscle soreness
Elizabeth Carol Dahlstrom
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Medical Nutrition Commons, Nutrition Commons, and the Physiology Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Dahlstrom, Elizabeth Carol, "Impact of protein supplementation on muscle recovery after exercise-induced muscle soreness" (2007).
Retrospective Theses and Dissertations. 14818.
https://lib.dr.iastate.edu/rtd/14818
Impact of protein supplementation on muscle recovery after exercise-induced muscle 
soreness 
 
 
by 
 
 
Elizabeth Carol Dahlstrom 
 
 
 
 
A thesis submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
MASTER OF SCIENCE 
 
 
 
Major: Nutritional Sciences 
 
Program of Study Committee: 
D. Lee Alekel, Co-Major Professor 
Rick Sharp, Co-Major Professor 
Don Beitz 
 
 
 
 
 
 
 
 
 
 
Iowa State University 
 
Ames, Iowa 
 
2007 
 
Copyright © Elizabeth Carol Dahlstrom, 2007.  All rights reserved. 
 
 
UMI Number: 1443131
1443131
2007
UMI Microform
Copyright
All rights reserved. This microform edition is protected against 
    unauthorized copying under Title 17, United States Code.
ProQuest Information and Learning Company 
300 North Zeeb Road
P.O. Box 1346
     Ann Arbor, MI 48106-1346 
 by ProQuest Information and Learning Company. 
  
ii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I dedicate this thesis to Dr. Paul Flakoll, 
 
who inspired me to become more than I thought I could be. 
 
Thank you, Dr. Flakoll 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
iii
TABLE OF CONTENTS 
 
LIST OF FIGURES            vi 
LIST OF TABLES           vii 
ACKNOWLEDGEMENTS         viii 
ABSTRACT             ix 
 
CHAPTER I:  GENERAL INTRODUCTION        1 
OBJECTIVE             1 
HYPOTHESES             1 
SPECIFIC AIMS             1 
SIGNIFICANCE OF STUDY           1 
LIMITATIONS OF STUDY           3 
DEFINITIONS             3 
 
CHAPTER II:  REVIEW OF LITERATURE        5 
INTRODUCTION            5 
HUMAN RESPONSES TO MUSCLE DAMAGE         5 
 Creatine Phosphokinase (CPK)         6 
 Delayed-Onset Muscle Soreness (DOMS)        6 
 Other Responses           7 
PROTOCOL SELECTION           7 
Eccentric Exercise Protocols          7 
Fast vs. Slow Velocity Eccentric Exercise        8 
High vs. Low Intensity Eccentric Exercise        9 
Protective Effect of Eccentric Exercise        9 
SUBJECT SELECTION            10 
Male vs. Female Subjects          10 
Number of Subjects           10 
Trained vs. Untrained Subjects         11 
  
iv
PROTEIN METABOLISM DURING AND AFTER EXERCISE       11 
Protein Supplements Before, During, and After Exercise      13 
 Whey Protein            14 
 Effects of Specific Amino Acids and Metabolites       15 
CARBOHYDRATE METABOLISM DURING AND AFTER EXERCISE      17 
Carbohydrate Supplements Before, During, and After Exercise     17 
COMBINED CARBOHYDRATE AND PROTEIN SUPPLEMENTS        18 
OTHER MUSCLE RECOVERY SUPPLEMENTS         20 
SUPPLEMENT PROTOCOL SELECTION          20 
Timing of Supplement          20 
 Dose Amount            21 
 Other Protocol Decisions          22 
FURTHER RESEARCH            22 
 
 
CHAPTER III:  IMPACT OF PROTEIN SUPPLEMENTATION ON MUSCLE 
RECOVERY AFTER EXERCISE-INDUCED MUSCLE SORENESS   23 
ABSTRACT             23 
KEY WORDS             24 
INTRODUCTION            24 
METHODS             25 
Subjects            25 
Pre-Baseline            25 
 Screening           25 
 Instructions for subjects         26 
Study Design and Protocol          27 
  Supplement intervention         27 
  Exercise protocol          27 
 Analysis of Records           28 
  
v
Analysis of Blood Samples          28 
Statistical Analysis           29 
RESULTS             29 
DISCUSSION             31 
CONCLUSION             33 
ACKNOWLEDGEMENTS           33 
REFERENCES             37 
 
CHAPTER IV:  GENERAL CONCLUSIONS        40 
 
REFERENCES            41 
 
APPENDIX A:  INFORMED CONSENT DOCUMENT        46 
 
APPENDIX B:  MEDICAL HISTORY/PHYSICAL ACTIVITY QUESTIONNAIRE     51 
 
APPENDIX C:            56 
MUSCLE SORENESS EVALUATION          56 
LEVEL OF EXERTION QUESTIONNAIRE          57 
ADVERSE EVENTS HEALTH FORM          58 
 
APPENDIX D:  RAW DATA           59 
 
APPENDIX E:  ADDITIONAL TABLES AND FIGURES        76 
 
 
 
 
 
 
  
vi
LIST OF FIGURES 
 
CHAPTER III:  IMPACT OF PROTEIN SUPPLEMENTATION ON MUSCLE 
RECOVERY AFTER EXERCISE-INDUCED MUSCLE SORENESS 
 
Figure 1  Serum CPK Activity (U/L) According to Treatment      35 
Figure 2  Muscle Soreness Evaluations (0-10 cm scale) According to Treatment   36 
 
APPENDIX E 
 
Figure 1  Effect of Day on CPK Activity (U/L) During All Trials Combined    77 
Figure 2  Effect of Day on Perceived Muscle Soreness (0-10 cm) During All Trials 
  Combined           78 
Figure 3  Serum CPK Activity (U/L) According to Trial      79 
Figure 4  Perceived Muscle Soreness (0-10 cm) According to Trial     80 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
vii
LIST OF TABLES 
 
CHAPTER III:  IMPACT OF PROTEIN SUPPLEMENTATION ON MUSCLE 
RECOVERY AFTER EXERCISE-INDUCED MUSCLE SORENESS 
 
Table 1 Subject Characteristics at Baseline          34 
Table 2 Dietary Intake of Subjects at Baseline According to Treatment    34 
 
APPENDIX D 
         
Table 1  Subject Height, Weight, and CPK Activity Data      59 
Table 2  Subject Perceived Muscle Soreness and Level of Exertion Data    61 
Table 3  Subject Blood Pressure and Heart Rate Data       63 
Table 4  Subject Dietary Intake Data from 24-hour Records      65 
Table 5            Subject Physical Activity Data from 24-hour Records    67 
Table 6  Subject Biodex Isokinetic Dynamometer Muscle Strength Indices    69 
 
APPENDIX E 
 
Table 1  Descriptive Statistics of Subjects at Baseline:  Level of Exertion (0-10 cm 
scale) and Physical Activity According to Treatment     76 
Table 2  Descriptive Statistics of Subjects:  CPK (U/L) and Muscle Soreness (0-10 
scale) at Each Time Point, According to Treatment      81 
Table 3 Effect of Day, Trial, and Treatment for Muscle Soreness Measures    82 
 
 
 
 
 
 
 
 
  
viii
ACKNOWLEDGEMENTS 
 
With deepest sincerity I would like to thank everyone who helped make this project a 
success. Thank you to my Major Professors, Dr. D. Lee Alekel and Dr. Rick Sharp. You both 
helped me design, plan, and interpret this study, and you taught me so much along the way. 
Dr. Alekel, you spent many hours working with me, improving my writing and technical 
skills, perfecting details, and showing me how to take multifarious information and present it 
in an understandable way. Dr. Sharp, you showed me the “big picture” of my research, 
clarified my complex study design and data, and taught me about exercise science and 
laboratory techniques. You both encouraged me to work hard and gave me confidence to do 
my best work, and I am grateful to both of you. Thank you to the wonderful Dr. Beitz:  you 
have served not only as my committee member, but also as my mentor, teacher, and 
supporter. An enormous thank you to Angela Olson, without whom I never could have 
conducted this study. Angela, you were with me every morning at 6 am, always ready to 
work and help me however you could. You kept me organized and efficient, and I am 
thankful we worked together. Thank you to Shawn Baier, who was with me in this study 
from the beginning and helped in the important preliminary stages of planning and designing 
the study, as well as teaching me the basics about exercise and the Biodex. Thanks to Anna 
Pederson, my statistician, who worked with me eagerly and quickly and helped to interpret 
my results. Thanks also to my fantastic 21 subjects and to Metabolic Technologies, Inc. for 
allowing me to use their Biodex machine. Thank you to Iowa State University and CDFIN 
for the many opportunities I have received, and to the FSHN and HHP Departments for all 
their knowledge and guidance. So many people have helped me in my graduate career and 
with this study, and I would like to say a special thanks to all of you: Diane Wilson, Marilyn 
Chrusciel, Elizabeth Blaser, Lisa Olson, Laura Hanson, Bill Colonna, Justine R. Hoover, 
Emily Lasley, Jeanne Stewart, and Dr. Kathy Hanson. Lastly, thank you to my family and 
friends, who constantly encouraged and supported me every step of the way. 
 
 
 
  
ix
ABSTRACT 
 
We investigated whether protein (PRO [0.4g/kg]) vs. carbohydrate (CHO [0.4g/kg]) 
vs. placebo nutrition supplements would alleviate muscle soreness when consumed 
immediately after eccentric exercise in 21 untrained men aged 18-30 years. During this 
double-blind randomized block study design, each subject completed three, 3-day trials 
(separated by >2 weeks), identical except for treatment, with each serving as his own control. 
Trials began with a bout of right leg eccentric exercise (Biodex), followed directly by 
treatment. At 0 (baseline), 24, and 48 hours, data were collected:  creatine phosphokinase 
(CPK) from pre-exercise blood samples, subjective muscle soreness questions, and strength 
tests (power, torque, work.). ANOVA indicated that exercise caused mild muscle damage, 
evidenced by an overall day effect (p≤0.0001) for muscle soreness, with the lowest median 
values (0 to 10 scale) on day 1 (0.7), increasing (p≤0.0001) on day 2 (3.2), and remaining 
elevated on day 3 (3.4). We also noted an overall day effect (p≤0.0001) for CPK, with lowest 
median values (U/L) on day 1 (136), increasing (p≤0.0001) on day 2 (235), and remaining 
elevated on day 3 (189). ANOVA revealed no significant treatment effect on indicators of 
soreness or damage during recovery. Our results indicated that a PRO or CHO supplement 
after exercise causing mild muscle damage did not facilitate muscle recovery in adequately 
nourished, healthy young men. 
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CHAPTER I:  GENERAL INTRODUCTION 
 
OBJECTIVE 
 The purpose of this study is to determine whether distinct nutritional supplements 
(protein vs. carbohydrate vs. placebo) cause different effects on muscle recovery after 
exercise-induced muscle soreness in untrained men aged 18 – 30 years. 
HYPOTHESIS 
1) A protein supplement will promote more rapid and greater muscle recovery after a 
single bout of exercise-induced muscle soreness compared with an isocaloric 
carbohydrate supplement. 
2) A protein supplement will promote more rapid and greater muscle recovery after a 
single bout of exercise-induced muscle soreness compared with a non-isocaloric 
placebo. 
3) A carbohydrate supplement will promote more rapid and greater muscle recovery 
after a single bout of exercise-induced muscle soreness compared with a non-
isocaloric placebo. 
SPECIFIC AIMS 
1) To determine whether a protein supplement promotes more rapid and greater muscle 
recovery than carbohydrate after exercise-induced muscle soreness in untrained men 
aged 18 – 30 years by measuring plasma creatine phosphokinase (CPK) activity. 
2) To determine whether a protein supplement promotes more rapid and greater muscle 
recovery than placebo after exercise-induced muscle soreness in untrained men aged 
18 – 30 years by measuring plasma CPK activity. 
3) To determine whether a carbohydrate supplement promotes more rapid and greater 
muscle recovery than placebo after exercise-induced muscle soreness in untrained 
men aged 18 – 30 years by measuring plasma CPK activity. 
SIGNIFICANCE OF STUDY 
Exercise-induced muscle soreness is thought to be caused by a mechanical disruption 
of sarcomeres, causing impaired excitation-contraction coupling and calcium signaling, 
followed by activation of calcium-sensitive degradation pathways. Eccentric exercise in 
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particular causes muscle soreness and microdamage and large increases in serum CPK 
activity (Evans 1991).  Muscle damage is recognized by ultra-structural changes in muscle 
architecture, increased muscle proteins and enzymes (such as CPK) in the bloodstream, loss 
of muscular strength and range of motion, and muscle soreness (Evans 1991). In this study, 
some of these muscle damage characteristics will be recorded to track muscle soreness. 
 During exercise, energy is used for contraction and is directed away from protein 
synthesis. Amino acids are also directed away from protein synthesis and are instead used to 
form glucose for additional energy. After exercise, amino acids and/or energy may be 
limiting and thus prevent optimal muscle protein synthesis (Evans 1991; Ohtani et al 2006). 
Hence, a protein supplement immediately after exercise has considerable potential to 
decrease muscle damage and soreness. In previous studies, increases in whole body and 
muscle protein accretion were noted when a protein supplement was ingested immediately 
following exercise. Studies reported that amino acid supplements given after exercise led to 
quicker recovery from muscle fatigue, decreased plasma CPK activity, decreased muscle 
soreness, and prevented exercise-induced proteolysis (Ohtani et al 2006; Nissen et al 1996). 
Further research suggested that post-exercise protein ingestion is most beneficial to muscle 
protein accretion when consumed immediately after exercise versus several hours later. 
 Current dietary recommendations for athletes are similar to those for the general 
population, but they emphasize carbohydrate and fluid intake (ADA 2000). The purpose of 
this recommendation is not to decrease muscle soreness, but rather to ensure that sufficient 
glycogen stores are available for muscle use and to avoid dehydration. It is also 
recommended that athletes consume extra protein (1.2-1.7 g/kg body weight/day) to have 
adequate muscle-building “supplies” (ADA 2000). However, it is unknown which 
macronutrient will be most effective in decreasing muscle soreness and increasing muscle 
recovery when consumed immediately after exercise. It is unclear how the nutrient supply 
affects muscle soreness. Past studies examined the effects of nutrition on exercise; several 
reported that, when compared with carbohydrate-only supplements, protein/carbohydrate-
containing supplements led to lower CPK activity, reduced muscle soreness, and 
improvements in time to fatigue (Wojcik et al 2001; Saunders et al 2004). More research is 
necessary, however, to fully understand the effects of protein and carbohydrate supplements 
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on muscle soreness. Therefore, this study compares the effects of protein, carbohydrate, and 
placebo on muscle recovery after a single bout of exercise-induced muscle soreness. 
LIMITATIONS OF STUDY 
 The study did not include a random sample of participants, but rather a convenience 
sample of self-selected male volunteers between the ages of 18 and 30 years. Hence, the 
results may not be generalizable to the entire male population. Also, this study did not 
include females, and thus conclusions from the data cannot be drawn for females. In addition, 
this study evaluated a relatively small sample size of 21 people. A trial with a greater number 
of subjects would provide greater statistical power for detecting small changes, which may 
not have been detectable because of inherent inter-individual variability. 
 Another limitation is the extent to which we could monitor the subjects’ physical 
activity. Although the subjects were instructed to refrain from physical activity for one week 
before each trial, their actual physical activity was not quantified. Thus, their physical 
activity may have had an undetectable effect on muscle soreness and CPK activity. Also, this 
study did not examine inflammatory markers that may result from or have had an effect on 
muscle damage. Although each subject’s diet was discussed with him and monitored, dietary 
intake was not controlled per se, allowing for inter-individual variation. However, the intent 
of the study was to include free-living men.  
 The exercise bouts were performed on a Biodex machine, which uses a person’s own 
resistance to determine the level of power output. Although subjects were strongly 
encouraged to work “as hard as they can”, the work performed from subject to subject 
typically varies. However, because each person served as his own control, the subject’s effort 
should not have been a major issue as long as each person performed similarly from trial to 
trial. 
DEFINITIONS 
Concentric action - a shortening of a muscle during its contraction 
Delayed onset muscle soreness (DOMS) - muscle soreness or discomfort that appears 24 to 
48 hours after exercise 
Eccentric action - a lengthening of the muscle during its contraction; controls speed of 
movement caused by another force 
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Isokinetic exercise - exercise in which the rate of movement is constantly maintained through 
a specific range of motion although maximal force is exerted 
Isometric exercise - an activity in which the muscles exert force but do not visibly change in 
length (i.e., pushing against a wall) 
Isotonic exercise - an activity in which the muscles exert force and change in length as they 
lift and lower resistance (i.e., bicep curls) 
Muscular strength - the ability of the muscle to generate the maximum amount of force 
Level of exertion evaluation - scale of 0-10 that rates how much a person feels he/she is 
exerting during a particular exercise set 
Peak torque - the maximal torque value that occurs in the range of movement 
Power - the product of torque and angular velocity, or work divided by time 
Range of motion - the angular displacement between the start and stop angles 
Repetition - the number of times an exercise is repeated within a single exercise “set” 
Set - a group of repetitions of a particular exercise 
Work - calculated as a measure of strength when torque is the unit of measurement 
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CHAPTER II:  REVIEW OF LITERATURE 
 
INTRODUCTION 
In general, unaccustomed exercise causes muscle damage. The sensation of muscle 
damage is often referred to as delayed onset muscle soreness (DOMS). DOMS usually begins 
within 24 hours and peaks within 48 hours after exercise. The severity of DOMS depends 
upon many factors, perhaps most prominently on exercise intensity and type and the training 
level of the individual (Evans 1991). 
Two general types of exercise muscle action exist:  concentric and eccentric actions. 
A concentric action occurs when a skeletal muscle contracts and shortens, whereas an 
eccentric action occurs when a skeletal muscle lengthens as it produces force (Evans 1991). 
For example, a concentric action is lifting a weight, and an eccentric action is lowering the 
weight (Evans 1991). Intense eccentric exercise typically causes extensive muscle damage, 
whereas an equal amount of concentric exercise may cause very little damage (Newham et al. 
1983b). Compared with concentric actions, eccentric actions cause more severe muscle 
damage, DOMS (Newham et al. 1983b), and increased plasma creatine phosphokinase (CPK) 
activity (Gleeson et al. 1995). The difference in muscle damage is thought to be the result of 
different fiber recruitment patterns and the fact that greater tension per muscle fiber is 
generated under eccentric exercise conditions (Newham et al. 1983c). This greater force-to-
fiber ratio causes greater muscle damage (Evans 1991). 
HUMAN RESPONSE TO MUSCLE DAMAGE 
 Following exercise-induced muscle damage in humans, several responses are evident. 
However, the extent of damage is not immediately evident; muscle damage seems to peak 
one to three days after the exercise occurs (Newham et al. 1983b). This is demonstrated from 
muscle biopsies and increased CPK activity (Newham et al. 1983b). Common responses to 
exercise-induced muscle damage include increased CPK, DOMS, decreased peak torque, 
decreased power output, and decreased range of motion (Evans 1991). 
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Creatine Phosphokinase (CPK) 
Perhaps the best-studied response to muscle damage is that of increased CPK activity, 
and thus CPK has been used as the most common indicator of skeletal muscle damage after 
muscular exercise: 
CPK 
ADP + creatine phosphate →→→→→ ATP + creatine 
 
Eccentric exercise produces a much larger increase in CPK, as noted in a study 
(Newham et al. 1986) that compared uphill walking (concentric exercise) with downhill 
walking (eccentric exercise). This study found that the eccentric exercise (700-1500 IU/L) 
caused much greater CPK activity than did the concentric exercise (60-200 IU/L). Another 
similar study (Newham et al. 1983a) found that subjects participating in eccentric stepping 
exercise (up to 34,500 IU/L) showed a much greater CPK response than did subjects 
participating in concentric stepping (less than 400 IU/L). The response of CPK to exercise is 
extremely variable and is influenced by several factors, including exercise type, intensity, 
and the training level of individuals. However, it is also important to note that there is 
enormous inter-individual variability, with subjects who perform identical activities often 
showing vastly different CPK activity increases (Evans 1991). Although the exact reasons for 
this phenomenon are unknown, it is suspected by researchers that the large variability of the 
CPK response after exercise is related to the variability of exercise-induced muscle damage 
(Nosaka et al. 1996). Thus, it is important that each subject serves as his/her own control, 
thereby minimizing the effect of inter-individual variability in exercise-induced muscle 
damage. 
Delayed-Onset Muscle Soreness 
Another observed response, usually occurring from one to five days following 
exercise, is DOMS, often recorded as a feeling of muscle soreness, tenderness, or stiffness. 
The exact cellular mechanism causing DOMS is unknown, but two hypotheses include cell 
membrane damage leading to disruption of calcium homeostasis and/or structural damage 
from high tension in the contractile/elastic system (Armstrong et al. 1984). Eccentric exercise 
causes greater DOMS than concentric exercise; in fact, concentric exercise often results in no 
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detectable DOMS (Newham et al. 1983a). Intensity and duration of exercise are also 
important factors in DOMS. Although not dangerous in itself, DOMS may increase the risk 
of further injury if an individual exercises subsequently without allowing time for the muscle 
micro-damage to heal (Cheung et al. 2003). In addition, DOMS can cause decreased joint 
range of motion and peak torque, as well as alterations in muscle sequencing and recruitment 
patterns. This may cause unaccustomed stress to be placed on muscle ligaments and tendons 
(Cheung et al. 2003). Many treatments have been attempted to decrease DOMS, such as 
pharmaceuticals, herbal remedies, stretching, massage, and various nutrition supplements, 
but none have been demonstrated as consistently successful (Connolly et al. 2003). Light 
concentric physical activity does not seem to have an effect on the recovery from previous 
muscle damage caused by eccentric exercise, although it may have a temporary analgesic 
effect on DOMS (Zainuddin et al. 2006). 
Other Responses 
Decreased peak torque, decreased power output, and decreased range of motion are 
other consistent human responses to muscle damage, and they are commonly used in research 
studies to monitor muscle damage and recovery after exercise (Chapman et al. 2006; Vincent 
et al. 1997; Paschalis et al. 2005b). 
PROTOCOL SELECTION 
 Many possibilities exist when designing a research protocol for muscle-damaging 
eccentric exercise. This section indicates some of the most effective protocols for inducing 
muscle damage in a research setting. 
Eccentric Exercise Protocols 
Several different eccentric exercise techniques may be used to incur muscle damage, 
such as running downhill (Newham et al. 1986), stepping down (Newham et al. 1983a), or 
action of the elbow flexors (Chapman et al. 2006) or knee extensors (Paschalis et al. 2005a) 
on a dynamometer. Each protocol has benefits and downfalls, whereas the magnitude of 
muscle damage varies among models. A study involving 11 young healthy untrained men 
examined indicators of muscle damage by comparing knee and elbow eccentric exercises 
using the same relative intensity of exercise (Jamurtas et al. 2005). The data found similar 
changes in DOMS, but changes in CPK and peak torque were larger from the arm compared 
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with leg exercises. The study concluded that the magnitude of muscle damage was greater 
and the recovery slower after exercising the elbow flexors verses the knee extensors 
(Jamurtas et al. 2005). 
However, exercising the knee extensors may be the best choice, depending upon the 
intent of the research. Some studies desire only a moderate degree of exercise-induced 
muscle damage; this causes the study to be more similar to real life. Typically, eccentric 
exercise with the knee extensors is performed on a dynamometer, such as the Biodex 
isokinetic dynamometer, a machine created for physical therapy patients. A common 
protocol is for a person to use one leg to perform several sets of maximal voluntary 
repetitions at a particular angular velocity, with sets separated by a short rest period. For 
instance, one recent study (Paschalis 2005a) induced muscle damage eccentrically with 10 
healthy male volunteers (age 22-24 years) who performed 120 (12x10) maximal voluntary 
repetitions on one leg at the angular velocity of 60 degrees/second (deg/s). Another study 
(Babul et al. 2003) had subjects perform 300 maximal voluntary eccentric contractions (30 
sets of 10 repetitions per minute) on a dynamometer with one leg at the angular velocity of 
30 deg/s. As these studies indicate, eccentric exercise with the knee extensors as described is 
a common and accepted practice. 
Between sets of eccentric contractions, subjects are usually provided a short rest 
period to allow recovery from the previous bout. This rest increases the amount of peak 
torque that subjects can produce during the next set. The length of this rest period varies 
among studies, but a recent study (Parcell et al. 2002) reported that during a common 
isokinetic strength test protocol, a rest period of at least 60 seconds between sets was 
necessary for recovery before the next set to allow the subjects to produce their maximum 
peak torque. Also, faster velocities of exercise required longer rest periods to recover. 
Fast vs. Slow Velocity Eccentric Exercise 
It is currently debatable whether fast or slow velocity eccentric exercise causes 
greater muscle damage. One recent study (Chapman 2006) used 12 untrained subjects to 
perform a series of slow velocity isokinetic eccentric elbow flexions with one arm (30 deg/s) 
and fast velocity exercises on the other arm (210 deg/s), separated by 14 days. Using 
measures of CPK, maximal torque, and muscle soreness, this study found that fast velocity 
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eccentric exercise caused greater muscle damage than slow velocity exercise. Another very 
similar study (Paddon-Jones et al. 2005) found that muscle soreness severity was similar 
from two exercise velocities, but the fast exercises caused peak muscle soreness 48 hours 
later than the slow exercises. This study concluded that the velocity of eccentric exercises 
differentially influenced the magnitude and time course of muscle damage markers. 
High vs. Low Intensity Eccentric Exercise 
Another recent study (Paschalis et al. 2005b) compared the effects of equal volumes 
(equal total work performed) of high verses low intensity eccentric exercise on muscle 
damage. This study enrolled 12 untrained healthy young men to undergo two isokinetic 
quadriceps eccentric exercise sessions, one with each leg, separated by two weeks. Subjects 
first performed high intensity eccentric exercise consisting of 12 sets of 10 maximal 
voluntary efforts, followed by low intensity eccentric exercise performed continuously at 
50% peak torque until the total work performed was equal to the high intensity exercise. Peak 
torque indicators, CPK activity, DOMS, and range of motion were measured at 0, 24, 48, 72, 
and 96 hours post-exercise. The study results indicated similar effects of high versus low 
intensity eccentric exercise on muscle damage, but high compared with low intensity 
exercise caused a larger decrease in muscle performance as measured by peak torque 
(Paschalis et al. 2005b). 
Protective Effect of Eccentric Exercise 
In sedentary subjects, only one bout of eccentric exercise can cause a “protective 
effect” on muscle damage that may last for several weeks or months. A low amount of 
eccentric exercise, causing no perceivable muscle damage or DOMS, is sufficient to cause a 
protective effect against, and significantly improve recovery from, further eccentric exercise 
(Paddon-Jones et al. 2001). One study (Byrnes et al. 1985) compared DOMS and CPK 
activity in three groups of subjects. All groups performed identical eccentric exercise, and 
then one of the groups repeated the same eccentric exercise 3, 6, or 9 weeks later. The results 
for the groups that exercised 3 or 6 weeks later indicated that subjects had significantly 
smaller DOMS scores and CPK activity from the second trial compared with the first trial. 
However, the group that exercised 9 weeks later showed no difference in DOMS or CPK 
activity between the two exercise sets. Thus, this study concluded that a single eccentric 
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exercise bout caused a protective effect, preventing repeated extensive damage from a similar 
bout for up to 6 weeks. Hence, after the initial exercise, subjects typically experience 
protection against further eccentric exercise, with smaller increases in DOMS and CPK 
activity. Further, another similar study (Nosaka et al. 1991) found that the CPK increases 
were significantly smaller after a second bout of eccentric exercise performed 6 months after 
the first bout; this research group subsequently demonstrated that the protective effect lasted 
between 9 and 12 months (Nosaka et al. 2001). Thus, the precise duration of the protective 
effect is currently unknown, as is the mechanism of this protection. 
SUBJECT SELECTION 
Male vs. Female Subjects 
Subject selection for a study also presents many options, with previous research 
indicating the most appropriate subject sample to use. Males are superior subjects in studies 
measuring DOMS, because females’ sensations of pain and soreness are affected by estrogen 
concentration, as well as males’ inherent ability to create more torque, power, and work 
(Pincivero et al. 2003). A study examining the effect of estrogen on markers of muscle tissue 
damage found that an elevated estrogen concentration has a protective effect on muscle tissue 
following eccentric exercise, as demonstrated by lower CPK activity in the high-estrogen 
group of subjects (Carter et al. 2001). In contrast, another study found that women taking oral 
contraceptives (and thus having high circulating estrogen) had delayed strength recovery (as 
measured by maximal isometric strength) after eccentric exercise, as compared with women 
not taking oral contraceptives (Savage et al. 2002). Also, a study comparing gender-specific 
knee exercises found that during maximal effort muscle contractions, males were able to 
generate higher knee extensor and flexor torque, work, and power than were females, and 
males also showed a higher susceptibility to muscle fatigue (Pincivero et al. 2003). 
Number of Subjects 
Because of the large inter-subject variability of CPK activity, the necessary number 
of subjects needed for a study designed to determine eccentric exercise and its related effects 
is very difficult to ascertain based upon power studies. Examining these studies, subject 
numbers ranging from 5 to 20 is common. In addition, BMI ranging from 18 to 30 is also 
common (Zainuddin et al. 2006; Paschalis et al. 2005b; Eston et al. 1996; Nelson et al. 2004). 
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Trained vs. Untrained Subjects 
An individual’s previous training significantly affects the amount of muscle damage 
that results from eccentric exercise. One study (Vincent et al. 1997) compared trained 
individuals (at least 3 years of weightlifting experience) and untrained individuals (no regular 
resistance exercise for at least 3 years). After performing eccentric exercise on the legs, they 
measured the subjects’ DOMS (using a 100 mm visual analog scale), CPK activity, and peak 
torque on the Biodex isokinetic dynamometer. The results indicated that although trained 
subjects actually reported greater DOMS, the CPK activity was significantly lower than that 
of the untrained subjects. These results suggest that trained subjects can develop extensive 
soreness without the same increase in CPK activity observed in untrained subjects. 
PROTEIN METABOLISM DURING AND AFTER EXERCISE 
Following eccentric exercise, many changes in metabolism occur. Exercise increases 
energy expenditure up to 10-fold, and thus recovery from muscle damage is almost certainly 
affected by nutrition (Fielding et al. 2002). Although several research studies indicate 
changes in both protein and carbohydrate metabolism, the optimal nutrition that enhances 
muscle recovery is currently unclear. The type, dose, and time of intake of a nutrition 
supplement may all play a role in facilitating muscle recovery after eccentric exercise, but 
currently the best combination of these factors is unknown. 
 Protein is used after exercise in muscle cells for many purposes. Most significantly, it 
is used to build and repair tissue. Protein is not thought to be a main energy source during 
resistance exercise, but it has been estimated to contribute between 5-15% of energy during 
endurance exercise (Paul 1989). Protein can be converted to glucose through liver and 
muscle gluconeogenesis, with the latter only providing glucose for the local working muscle. 
Because physical activity improves protein utilization (Butterfield et al. 1984), protein 
balance is an important consideration during exercise. If muscle protein synthesis is greater 
than muscle protein breakdown, positive muscle protein balance prevails, and protein may be 
used for muscle growth and repair. However, if muscle protein breakdown is greater than 
muscle protein synthesis, negative muscle protein balance prevails, and sufficient protein is 
not available for muscle growth and repair (Evans 1991). 
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Exercise has a significant acute effect on protein metabolism. After eccentric 
exercise, both muscle protein breakdown and synthesis increase for up to 48 hours after 
exercise ceases (Tipton et al. 1998). For muscle protein synthesis to increase, ample amino 
acids must be delivered and transported into the myocytes. Increasing dietary amino acids 
after exercise has been reported to increase amino acid availability, and thus increased 
muscle protein synthesis and breakdown (Tipton et al. 1998). Indeed, the presence of 
increased dietary amino acids resulted in greater muscle anabolism (Tipton et al. 2001b). In 
addition, several studies have found that the ingestion of a protein and/or carbohydrate 
supplement immediately after eccentric exercise caused an acute increase in protein net 
balance (Gibala 2000), whereas a negative protein balance occurred in the fasted state (Wolfe 
2006). Thus, exercise causes an increased requirement for dietary protein. Interestingly, a 
recent study showed that the rate of human muscle protein synthesis is regulated by sensing 
the concentration of extracellular, not intramuscular, amino acid availability (Bohe et al. 
2003). However, the amount of amino acids required, the optimal amino acid profile, and the 
resultant net gain in muscle protein synthesis are currently unknown (Wolfe 2006). Knowing 
that sufficient protein is necessary for muscle anabolism after exercise, and considering that 
nutrients repair muscle damage, it is logical to hypothesize that increased dietary protein 
intake after muscle-damaging exercise may speed muscle recovery. 
Previous studies have shown additional benefits of protein supplementation. When a 
mixture of amino acids was ingested chronically, recorded beneficial effects included faster 
recovery time from eccentric exercise-induced muscle fatigue, increased blood oxygen-
carrying capacity (Ohtani et al. 2006), decreased bacterial/viral infections, decreased 
muscle/joint problems, and decreased heat exhaustion (Flakoll et al. 2004). 
Currently, the current United States Recommended Daily Allowance (RDA) for 
protein for the average American is 0.8 g/kg per day. However, many factors influence a 
person’s protein requirement, such as exercise intensity, exercise training, exercise type, 
energy balance, gender, age, timing of nutrient intake, and subsequent exercise sessions 
(Lemon 1998). Thus, many research studies provide evidence that exercising individuals 
have a higher protein requirement. One study (Meredith et al. 1989) fed 12 endurance-trained 
men 0.6, 0.9, or 1.2 g/kg per day of high-quality protein over three separate 10-day periods, 
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while maintaining training and constant body weight. Whole-body nitrogen measurements 
showed that all subjects were in negative nitrogen balance at the intake of 0.6 g/kg per day, 
seven men were in negative nitrogen balance at the intake of 0.9 g/kg per day, and only one 
man was in negative nitrogen balance at the intake of 1.2 g/kg per day. Researchers 
concluded that, regardless of the age of the subject, the estimated protein requirement was 
0.94 +/- 0.05 g/kg per day. Also, they reported that protein intake increased whole body 
protein flux and synthesis. A 40-day study (Consolazio et al. 1975) researched two groups of 
men, consuming either 1.4 or 2.8 g/kg per day of protein. Subjects performed fairly heavy 
physical activity every day and had significant nitrogen losses from sweat. The researchers 
found that the group consuming 1.4 g/kg per day of protein had adequate protein, and that 
additional protein did not enhance work performance. However, the 2.8 g/kg per day protein 
intake caused increased body protein stores and muscle mass. Thus, the researchers 
concluded that the lower protein intake, or ~100 g of protein/day, was adequate for men 
performing heavy exercise. For a 75 kg man, this equals 1.33 g/kg per day. Interestingly, the 
researchers also noted that nutrient and nitrogen losses during profuse sweating caused 
calculation error that may seriously invalidate the accuracy of metabolic balance studies. 
Thus, because of sweating, an exact calculation of nitrogen balance during heavy exercise is 
virtually impossible to determine, unless nitrogen losses are accounted for in sweat. 
Studies like these have led the American Dietetic Association and the American 
College of Sports Medicine to recommend protein intake between 1.2 to 1.4 g/kg body 
weight per day for endurance athletes and 1.6 to 1.7 g/kg body weight per day for resistance 
and strength-trained athletes (ADA 2000). Currently, there is no evidence that protein intake 
in these ranges will cause adverse effects in healthy individuals (Lemon 1998). 
Protein Supplements Before, During, and After Exercise 
 Several studies have concluded that ingesting protein supplements before, during, or 
after exercise can decrease muscle damage and/or increase muscle recovery. Recently 
researchers (Sugita et al. 2003) compared the effects of ingesting an amino acid mixture or 
placebo for 10 days after eccentric exercise. The amino acid mixture was 5.6 g per dose, and 
it contained 12 amino acids, with glutamine, arginine, leucine, isoleucine, and valine 
composing over 50% by weight. The study included young, healthy males (19-21 years) who 
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completed two trials (separated by two months), with subjects ingesting one supplement after 
each trial. Muscle peak torque and DOMS were recorded at several time points. At certain 
time points, the results indicated a significant smaller decline in muscle strength (isometric 
peak torque) in the amino acid group compared to the placebo group. Also, most subjects 
reported less DOMS after ingesting the amino acid mixture. The researchers concluded that 
the ingestion of the amino acid mixture sped the rate of extensor muscle recovery, caused 
larger peak torque values, and caused decreased DOMS values. Thus, amino acids may 
prevent muscle damage and/or promote muscle recovery. 
 Another crossover study (Ohtani et al. 2006) instructed 24 untrained males to ingest 
either an amino acid mixture or placebo before and after endurance exercise. Subjects 
completed two trials (separated by four weeks), and in each trial they consumed one of the 
supplements. The researchers found that when subjects ingested the amino acid supplement, 
increases in CPK activity and muscle soreness were significantly smaller than after ingesting 
placebo. This study indicated that amino acid supplementation with exercise caused 
decreased muscle damage and/or increased muscle recovery. 
 A 54-day study of 387 young, healthy, male marines assessed perceived muscle 
soreness (DOMS) using a 1-10 continuous range self-reported evaluation scale (Flakoll et al. 
2004). The marines ingested supplements (protein, carbohydrate, lipid, respectively, in 
grams) with predominantly protein (10, 8, 3), carbohydrate (0, 8, 3), or placebo (0, 0, 0) 
immediately post-exercise every other day for the entire study. On both days 34 and 54, the 
results indicated that the protein supplement caused significantly decreased muscle soreness 
compared to carbohydrate or placebo. These studies, as well as many others, indicate that 
protein supplements may have a significant effect on muscle recovery after exercise-induced 
muscle damage. 
Whey Protein 
Protein is available from many food sources, including both animal and plant sources. 
However, different sources yield protein that varies greatly in amino acid content, 
bioavailability, and biological value. Several studies have compared various proteins and 
their effects under exercise conditions. A recent study (Tipton et al. 2004) compared the 
effect of ingesting either 20 g of casein, 20 g of whey protein, or placebo one hour after leg 
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extension exercises. Blood samples showed that ingestion of both protein types caused 
similar increases in muscle protein balance and muscle protein synthesis. However, in a 
study (Morifuji et al. 2005) comparing the effects of casein and whey protein in exercising 
rats, researchers found that rats consuming whey protein significantly increased both their 
skeletal muscle glycogen content and liver glycogen content more than rats consuming 
casein. Interestingly, a study comparing lean body mass gains of weightlifters found that soy 
protein and whey protein both promoted training-induced lean body mass gain (Brown 
2004). However, a review comparing several recent studies concluded that when balanced 
quantities of total protein and energy are consumed, milk proteins (whey and casein) are 
more effective than soy protein in stimulating amino acid uptake and protein turnover in 
skeletal muscle after resistance exercise (Phillips et al. 2005). 
Effects of Specific Amino Acids and Metabolites 
It has been suggested that only essential amino acids (EAA) are required for the 
increase in net muscle protein balance, and nonessential amino acids (NEAA) are not 
necessary. One study (Borsheim et al. 2002) compared the effects on net muscle protein 
balance from one of two doses of amino acids:  either 6 g of orally administered EAA, or a 
mixture of 3 g EAA and 3 g NEAA. The data indicated that the pure EAA dose stimulated 
twice the net muscle protein balance response compared with the EAA+NEAA mixture, and 
the researchers concluded that NEAA are not necessary for stimulation of net muscle protein 
balance. Another study (Tipton et al. 1999) provided subjects with either 40 g of a mixed 
amino acid (EAA+NEAA) solution, 40 g EAA solution, or a placebo solution after a bout of 
resistance exercise. The results indicated that net muscle protein balance significantly 
increased with the EAA+NEAA or EAA solutions as compared with the placebo solution. 
However, net balance was similar for NEAA+EAA and EAA. Thus, researchers found that 
the NEAA mixture did not affect muscle protein balance; EAA was the determinant. It is 
difficult to compare the results of these two studies because the investigators used such 
disparate amounts of amino acids. 
The branched chain amino acids (BCAA) leucine, valine, and isoleucine have unique 
structures. They are readily oxidized in skeletal muscle, and they are regulated in skeletal 
muscle by a specific complex -- the branched-chain alpha-keto acid dehydrogenase 
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(BCKDH) complex. Exercise activates the BCKDH complex, causing increased BCAA 
catabolism and possibly an increased BCAA requirement (Shimomura et al. 2006). Because 
of their prominent role in muscle metabolism, BCAA have often been researched as possible 
exercise performance enhancers. Researchers have developed a number of theories to explain 
how BCAA increase exercise performance. One is that BCAA delay the onset of central 
nervous system fatigue; another is that BCAA extend performance by serving as substrates 
for energy expenditure (ADA 2000). It also has been suggested that exercise increases the 
catabolism of BCAA, causing an increased requirement for BCAA. Supplementation with 
BCAA has been reported to decrease the breakdown of muscle protein during exercise, and 
thus a BCAA supplement may attenuate muscle damage due to exercise and increase 
recovery from damage (Shimomura et al. 2006). 
Researchers have studied the effect of BCAA on muscle recovery after exercise. One 
study (Coombes et al. 2000) separated 16 male subjects into two groups:  one group received 
BCAA supplements for 14 days before exercise, and the other group did not. Before exercise, 
normal blood values were recorded for both groups. After prolonged cycling exercise, 
however, the BCAA group had significantly decreased CPK activity, suggesting that the 
BCAA supplement reduced muscle damage. A recent study (Shimomura et al. 2006) 
demonstrated that a BCAA supplement before squat exercise decreased DOMS, suggesting 
that BCAA may increase muscle recovery after exercise. However, results of studies that 
have used BCAA are inconsistent and currently their use as exercise performance enhancers 
is unclear (ADA 2000). 
Beta-hydroxy-beta-methylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) are 
metabolites of leucine. Some researchers have suggested that they also may decrease muscle 
damage following eccentric exercise. A recent study (van Someren et al. 2005) compared the 
effects of a HMB (3 g) + KIC (0.3 g) supplement vs. placebo when given daily for 14 days 
prior to a bout of muscle-damaging eccentric exercise. Muscle damage indices, including 
CPK and DOMS, were measured pre-exercise and at 1, 24, 48, and 72 hours post-exercise. 
Compared with placebo, the results indicated that the HMB+KIC supplement significantly 
decreased CPK activity and DOMS. Thus, the researchers concluded that the HMB+KIC 
supplement diminished the muscle damage from a single bout of eccentric exercise. 
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Similarly, another study (Nissen et al. 1996) compared the effects of various amounts of 
HMB supplements during resistance training. After measuring indicators including CPK and 
body composition, researchers reported that HMB in association with resistance training 
decreased exercise-induced muscle damage and caused increased gains in muscle function. 
CARBOHYDRATE METABOLISM DURING AND AFTER EXERCISE 
 Muscle cells need a constant supply of energy to properly function during exercise. 
This energy originates most directly from carbohydrate sources. The body uses muscle 
glycogen as the first main source of energy, and it then shifts to blood glucose if necessary 
(ADA 2000). It is well known that skeletal muscle glycogen is a substrate for energy 
metabolism within the working muscle during exercise, but muscle-damaging exercise may 
result in impaired glycogen synthesis. Researchers have found (Sherman et al. 1983; Zehnder 
et al. 2004) an association between delayed muscle damage and impaired glycogen repletion 
following endurance exercise. Because muscle-damaging exercise is thought to alter muscle 
cell membrane integrity, eccentric exercise results in decreased insulin sensitivity and 
glucose availability to the muscle cell (Evans 1991). Because of these many functions of 
carbohydrate, researchers have investigated whether carbohydrate supplements may decrease 
muscle damage after exercise, but thus far evidence for this is sparse (Close et al. 2005). 
Currently, the carbohydrate recommendations for athletes range from 6 to 10 g/kg body 
weight per day (ADA 2000). 
Carbohydrate Supplements Before, During, and After Exercise 
 Some research indicates that carbohydrate ingestion replenishes muscle glycogen to a 
greater extent than placebo (Tarnopolsky et al. 1997), but other research has not shown this 
effect. In a recent study (Zehnder et al. 2004), researchers examined the effect of post-
exercise carbohydrate ingestion on glycogen repletion in 20 subjects with depleted glycogen 
stores. After glycogen depletion, one group of subjects performed eccentric exercise and one 
group rested. During the next 24 hours, both groups consumed a high carbohydrate diet. The 
results indicated that the high carbohydrate diet did not replenish glycogen stores after 
eccentric exercise. 
Carbohydrate is the primary source of energy for working muscles, and thus scientists 
have suggested that increased carbohydrate intake before or after eccentric exercise may 
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decrease muscle damage and DOMS. However, some current studies have not found this 
evidence in controlled clinical trials. A recent study (Close et al. 2005) included 12 subjects 
who performed two identical downhill runs, one after a high carbohydrate diet and one after a 
low carbohydrate diet. After this eccentric exercise, all subjects developed similar DOMS 
and CPK activity regardless of treatment. The researchers concluded that carbohydrate status 
before exercise had no effect on muscle damage from eccentric exercise. Similarly, another 
study (Nelson et al. 2004) compared the effect of inadequate carbohydrate intake on muscle 
soreness after eccentric exercise. This study split 33 young male subjects into three groups:  
one glycogen depleted, one glycogen depleted and then repleted, and one received no 
treatment. Researchers measured DOMS and isometric force production before and after 
treatment. The results indicated DOMS and decreased isometric peak force for all groups, but 
no differences were seen among any of the groups. The researchers concluded that 
inadequate carbohydrate intake did not affect DOMS and muscle strength. 
Unlike dietary protein, dietary carbohydrate causes a negligible increase in protein 
synthesis. In one study (Levenhagen et al. 2002), an intake of 15 g of carbohydrate (verses 
fasting) immediately post-exercise did not improve whole body or muscle protein synthesis. 
A set of studies compared three groups of subjects, all performing prolonged resistance leg 
exercises. After exercise, each group consumed either:  100 g of a protein/carbohydrate 
mixture, 100 g of carbohydrate, or placebo. Muscle protein balance was measured by blood 
samples and muscle biopsies. The researchers found that the ingestion of carbohydrate 
improved net leg protein balance after exercise (Borsheim et al. 2004b), but its effect was 
minor compared to the identical study with amino acid ingestion (Borsheim et al. 2004a). 
Thus, although many studies have found that carbohydrate consumed after exercise is 
beneficial to subjects, its usefulness compared with protein still requires additional research. 
COMBINED CARBOHYDRATE AND PROTEIN SUPPLEMENTS 
Protein and carbohydrate each cause specific effects on muscle metabolism. Several 
researchers have examined the effect of ingesting a combination protein and carbohydrate 
supplement, investigating the theory that an interactive effect may cause greater gains than 
with either singular supplement (Wolfe 2002). Consuming protein with carbohydrate does 
not seem to increase glycogen repletion, but it may be useful for muscle protein repair (ADA 
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2000). Compared to placebo, research indicated that a carbohydrate/protein supplement after 
exercise consistently resulted in lower CPK values (Seifert et al. 2005), with several studies 
providing evidence. 
Researchers (Borsheim et al. 2004a) compared the effects of two isocaloric 
supplements:  the first contained 100 g carbohydrate, whereas the second contained 77.4 g 
carbohydrate, 17.5 g whey protein, and 4.9 g amino acids. As assessed by blood samples and 
muscle biopsies, this study found that the protein + carbohydrate combination supplement 
stimulated muscle protein synthesis more than did the carbohydrate alone. Another study 
(Wojcik et al. 2001) compared the muscle damage of subjects who consumed a 
protein/carbohydrate, carbohydrate, or placebo beverage after eccentric exercise. The results 
indicated that CPK activity was least in the subjects consuming the protein/carbohydrate 
beverage. 
A recent study (Millard-Stafford et al. 2005) compared the effect of 6% carbohydrate, 
10% carbohydrate, or 8% carbohydrate + 2% protein on muscle recovery after exercise. The 
results showed that although CPK activity was similar among all groups, perceived muscle 
soreness was lower in the carbohydrate/protein group than with carbohydrate alone. Another 
study (Saunders et al. 2004) compared the effects of a carbohydrate beverage verses a 
protein/carbohydrate beverage on CPK activity in 15 male cyclists. The beverages were not 
isocaloric, but they were matched for carbohydrate content. Each subject, serving as his own 
control, completed two exercise sessions (separated by two weeks), consuming a different 
supplement each session. The researchers found that the peak post-exercise plasma CPK 
activity was 83% lower after the protein/carbohydrate trial than after the carbohydrate trial. 
Thus, the researchers concluded that the protein/carbohydrate beverage decreased muscle 
damage. However, further research is necessary to determine whether the results were 
because of the increased energy content of the protein/carbohydrate beverage, or if an 
isocaloric beverage containing protein and carbohydrate would produce the same results. 
From these studies, it seems fairly clear that a protein/carbohydrate supplement after exercise 
decreases muscle damage to a greater extent than a carbohydrate supplement. 
  
20
OTHER MUSCLE RECOVERY SUPPLEMENTS 
Many other nutrients have been researched as possible effectors on markers of 
exercise-induced muscle damage following eccentric exercise. A recent study (Rawsom et al. 
2001) compared the effects of oral creatine verses placebo on indicators of muscle damage in 
23 males (18-36 years) for 5 days before performing high-intensity eccentric exercise. 
However, the data indicated that the creatine supplement did not decrease muscle damage or 
enhance recovery. A similar study (Jakobi 2000) also found that short-term creatine 
supplement did not influence muscle force, delay time to muscle fatigue, or improve muscle 
recovery. Ibuprofen is an effective treatment in decreasing muscle soreness after eccentric 
exercise, but it did not assist in restoring muscle function (Tokmakidis 2003). Naproxen also 
decreased DOMS and increased peak torque, but it did not decrease CPK activity (Lecomte 
1998). 
SUPPLEMENT PROTOCOL SELECTION 
Timing of Supplement 
The timing of supplement ingestion is a very important consideration. Should the 
supplement be consumed days before, hours before, immediately before, during, immediately 
after, or hours after exercise? A recent study (Tipton et al. 2001a) examined whether an 
amino acid/carbohydrate supplement would cause a greater anabolic response before or after 
resistance exercise. Six healthy subjects each participated in two trials, either consuming the 
supplement immediately before or immediately after exercise. Blood samples and muscle 
biopsies in both trials indicated that amino acid delivery to the leg was elevated during and 
after exercise for two hours. However, when the supplement was ingested before exercise, 
amino acid delivery to the leg was significantly greater during and for the first hour 
following exercise. These results suggest that muscle protein synthesis is greater when the 
supplement is consumed immediately before exercise. In contrast, a more recent study 
(Tipton et al. 2006) examined whether these results also apply to the ingestion of whole 
protein, but the researchers found that the data were not similar. Seventeen subjects were 
assigned randomly to one of two groups:  one consumed whey protein immediately before 
exercise and the other consumed whey protein immediately after exercise. The exercise 
consisted of 10 sets of 8 repetitions of leg extension exercise. The results indicated that 
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amino acid uptake was not significantly different between the groups. Thus, the response of 
net muscle protein balance is not affected by the timing of ingestion, and whole protein does 
not produce the same result as does a combination of EAA+carbohydrate supplement. 
Another study (Levenhagen et al. 2001) compared the timing of ingestion after 
exercise. Ten subjects performed two trials, ingesting the same supplement composed of 10 g 
protein, 8 g carbohydrate, and 3 g fat during both trials. Subjects consumed the supplement 
either immediately after or three hours after one hour of exercise. Results showed that leg 
glucose uptake and leg protein synthesis both increased 300% more when the supplement 
was consumed immediately verses three hours later, indicating a significant advantage in 
consuming this supplement immediately after exercise. In summary, consuming nutrition 
supplements immediately after exercise clearly causes greater effects than consumption 
several hours post-exercise (ADA 2000). Further, supplement consumption immediately 
before or after exercise does not seem to make a significant difference. 
Dose Amount 
The amount of the dose administered in research studies varies considerably. Some 
studies administer doses that are identical for all subjects, such as 100 g carbohydrate for all 
subjects (Borsheim et al. 2004b). However, this may not be the best method, considering the 
great variability in body weight and thus different amounts of muscle mass and variation in 
metabolic rate from person to person. A more accurate method to dose subjects is to 
administer the supplement on a “gram supplement per kilogram body mass” basis. For 
instance, a person would receive 1.2 g supplement per kg body mass. The dose administered 
in studies (Williams et al. 2003; Wojcik et al. 2001; Berardi et al. 2006) varies greatly, but 
commonly is about 1.0 g protein/kg body weight. 
A recent study compared the effects of ingesting various doses of a protein 
supplement on exercise-induced muscle damage (Nosaka et al. 2006). Before and after 
endurance exercise on the elbow flexors, subjects ingested a total of either two or ten doses 
of supplement. The subjects consuming only two protein doses reported no significant 
differences in CPK activity or muscle soreness verses consuming placebo, but the subjects 
consuming ten doses showed significantly lower CPK activity and muscle soreness verses 
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consuming placebo. Clearly, the increased number of protein supplement doses had a 
significant effect on muscle recovery after exercise. 
Other Protocol Decisions 
To perform optimally during exercise, it is vital that individuals maintain normal fluid 
status. Thus, before, during, and after an exercise protocol, individuals must drink adequate 
fluids. However, exercise of moderate duration (less than 3 hours) does not require 
replacement of electrolytes (ADA 2000). Current research recommends intake of 
carbohydrate with fluids to increase exercise performance. This is especially important for 
individuals who exercise after an overnight fast. It is best that the carbohydrate consumed is 
glucose or sucrose, because fructose alone can cause diarrhea (ADA 2000). 
FURTHER RESEARCH 
 Although a plethora of research has been conducted on nutrient intake, metabolism, 
and recovery from exercise, clear conclusions have not yet been realized. Many research 
studies have reported convincing evidence as to the usefulness of protein and/or carbohydrate 
supplements after exercise, but many scientists remain unconvinced that these supplements 
are truly necessary or helpful (Williams 1999; Nemet et al. 2005; Kreider et a. 1993). Further 
research needs to be conducted to clarify the usefulness of protein and/or carbohydrate 
supplements after eccentric exercise to decrease muscle damage and/or increase muscle 
recovery. 
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ABSTRACT 
We investigated whether protein (PRO [0.4g/kg]) vs. carbohydrate (CHO [0.4g/kg]) vs. 
placebo nutrition supplements would alleviate muscle soreness when consumed immediately 
after eccentric exercise in 21 untrained men aged 18-30 years. During this double-blind 
randomized block study design, each subject completed three, 3-day trials (separated by >2 
weeks), identical except for treatment, with each serving as his own control. Trials began 
with a bout of right leg eccentric exercise (Biodex), followed directly by treatment. At 0 
(baseline), 24, and 48 hours, data were collected:  creatine phosphokinase (CPK) from pre-
exercise blood samples, subjective muscle soreness questions, and strength tests (power, 
torque, work.). ANOVA indicated that exercise caused mild muscle damage, evidenced by an 
overall day effect (p≤0.0001) for muscle soreness, with the lowest median values (0 to 10 
scale) on day 1 (0.7), increasing (p≤0.0001) on day 2 (3.2), and remaining elevated on day 3 
(3.4). We also noted an overall day effect (p≤0.0001) for CPK, with lowest median values 
(U/L) on day 1 (136), increasing (p≤0.0001) on day 2 (235), and remaining elevated on day 3 
(189). ANOVA revealed no significant treatment effect on indicators of soreness or damage 
during recovery. Our results indicated that a PRO or CHO supplement after exercise causing 
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mild muscle damage did not facilitate muscle recovery in adequately nourished, healthy 
young men. 
 
KEY WORDS:  eccentric exercise, creatine phosphokinase, muscle damage 
 
INTRODUCTION 
In general, unaccustomed exercise causes muscle soreness, which usually begins 
within 24 hours and peaks within 48 hours after exercise. Eccentric exercise, which occurs 
when a skeletal muscle lengthens as it produces force, particularly causes muscle damage. 
Common responses to exercise-induced muscle damage include increased creatine 
phosphokinase (CPK) (Gleeson et al. 1995), increased muscle soreness (Newham et al. 
1983b), decreased peak torque, decreased power output, and decreased range of motion 
(Chapman et al. 2006; Vincent et al. 1997; Paschalis et al. 2005b). Effective eccentric 
exercises include running downhill (Newham et al. 1986), stepping down (Newham et al. 
1983a), or action of the elbow flexors (Chapman et al. 2006) or knee extensors (Paschalis et 
al. 2005a) on a dynamometer. The extent of muscle damage, however, depends upon the 
gender (Pincivero et al. 2003), training status (Vincent et al. 1997), and/or nutrition status of 
the individual. 
 During exercise, amino acids are used to build and repair tissue as well as to supply 
energy, whereas carbohydrate is the primary energy source for muscle contraction. In the 
event that amino acids and/or carbohydrate are limiting during the course of exercise, optimal 
muscle protein synthesis and turnover (Ohtani et al. 2006; Tipton et al. 1998) may not 
proceed and muscle recovery may be impeded. Hence, nutrition supplements before or after 
eccentric exercise may significantly impact muscle damage and muscle recovery, and 
specifically a protein supplement has considerable potential to decrease muscle damage and 
soreness (Sugita et al. 2003; Ohtani et al. 2006). In previous studies (Tipton et al. 1998; 
Tipton et al. 2001b; Gibala 2000), increases in whole body and muscle protein accretion were 
noted when a protein supplement was ingested immediately following exercise. Studies 
reported that amino acid supplements given after exercise led to more rapid recovery from 
muscle fatigue, decreased plasma CPK activity, decreased muscle soreness, and lessened 
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exercise-induced proteolysis (Ohtani et al. 2006; Nissen et al. 1996; Flakoll et al. 2004) 
Further research (Levenhagen et al. 2001) suggested that post-exercise protein ingestion was 
most beneficial to muscle protein accretion when consumed immediately after exercise 
versus several hours later. Researchers (Sherman et al. 1983; Zehnder et al. 2004) also have 
investigated whether carbohydrate supplements decrease muscle soreness because of 
increased energy availability or muscle glycogen repletion. However, most researchers 
suggested that inadequate carbohydrate intake did not affect CPK activity (Close et al. 2005), 
muscle soreness (Nelson et al. 2004; Close et al. 2005), and muscle strength (Nelson et al. 
2004). 
The purpose of this study was to determine whether distinct nutritional supplements 
(protein vs. carbohydrate vs. placebo) cause different effects on muscle recovery after 
exercise-induced muscle soreness in untrained healthy men aged 18 – 30 years. Our 
hypotheses were that a protein supplement would promote more rapid and greater muscle 
recovery after a single bout of exercise-induced muscle soreness compared with carbohydrate 
or placebo, and that a carbohydrate supplement would promote more rapid and greater 
muscle recovery after a single bout of exercise-induced muscle soreness compared with 
placebo. 
 
METHODS 
Subjects 
Volunteers were required to be non-smokers, untrained, 18 –30 year old males, with a BMI 
in the range of 18.0 – 29.9 kg/m2. Subjects were required to refrain from medication or 
vitamin/mineral supplement use during the study. Each subject served as his own control. We 
excluded subjects who had recently increased their level of resistance training prior to 
participating in this study, whereas those who had maintained a relatively constant degree of 
physical activity were allowed to participate. 
Pre-baseline 
Screening. The Human Subjects Institutional Review Board at Iowa State University 
approved the study (IRB ID#05-341). The study design, purpose, and potential risks were 
explained to each subject, with an opportunity for each to ask questions. Prior to screening, 
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each subject signed an Informed Consent document. All portions of the study were carried 
out in the Human Metabolic Unit (HMU) on the Iowa State University campus. Prior to 
enrollment in the study, each volunteer was screened to determine eligibility and 
measurements were recorded for height, weight, blood pressure, and heart rate. Using height 
and weight, BMI was calculated for each subject. Bio-electrical impedance analysis (BIA) 
was used to assess body composition, with three measurements recorded and averaged for 
each subject. To further determine eligibility and screen for past or current health problems, 
each potential subject completed a medical history questionnaire and a physical activity 
questionnaire. To confirm eligibility, each potential subject also had an initial blood draw by 
venipuncture (8.5 mL vacutainer) that was analyzed by a certified clinical laboratory 
(Laboratory Corporation of America; Kansas City, MO) with chemistry profile results 
recorded for each subject. We excluded volunteers with evidence of hypertension, liver 
disease, kidney disease, diabetes, asthma, and/or abnormal blood values. We enrolled 
volunteers in the study who met all inclusion and exclusion criteria. 
 During screening each volunteer participated in an exercise test to measure leg 
flexion/extension muscle strength on the dynamometer (Biodex System 3 Isokinetic 
Dynamometer, Biodex Medical Systems; Shirley, NY), as well as participated in a short 
training session that explained the future exercise protocol. Muscle strength indicators 
recorded during this baseline test and all subsequent exercise tests were:  extension peak 
torque, extension maximum repetition total work, extension average power, extension 
average peak torque, flexion peak torque, flexion maximum repetition total work, flexion 
average power, and flexion average peak torque. 
Instructions for subjects.  Subjects were instructed to eat their normal diets before and during 
the study, but they were only allowed to drink two alcoholic drinks each day, beginning three 
days before and lasting until the completion of the trial. Also, subjects were instructed to 
refrain from any new or unusual physical activity beginning one week before and lasting 
until the completion of the trial. Each participant completed three, 3-day trial periods. 
Beginning three days before his first visit to the HMU, each subject began keeping a written 
24-hour diet record. This record continued until the first day of the trial (time = 0 hours), and 
thus the record did not include the protein or carbohydrate supplement administered during 
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the trial. Each subject also began recording his 24-hour physical activity record the day prior 
to the first day of the trial. This record continued until the end of each trial. 
Study Design and Protocol 
Supplement intervention.  This double-blind, crossover study was designed to compare the 
effects of protein, carbohydrate, and placebo beverage supplements on markers of muscle 
damage (CPK, muscle soreness questionnaire, muscle strength test). Each subject served as 
his own control, and thus completed the identical protocol three times, consuming one of the 
three supplements each time. The supplements were administered in random order, thus 
preventing a trial sequence effect. The supplements were composed of either:  1) Protein:  
whey protein (0.4 g/kg body weight) with cherry flavoring (Nectar! Whey Protein Isolate, 
Syntrax, SIO3 Inc.; Cape Girardeau, MO), dissolved in 1 cup water; 2) carbohydrate:  sugar 
(0.4 g/kg body weight and cherry Kool-Aid® (Kraft Foods Global, Inc.; Glenview, IL), 
dissolved in 1 cup water; 3) placebo:  Splenda® (McNeil Nutritionals, LLC; Ft. Washington, 
PA) (0.0485 g/kg body weight) and cherry Kool-Aid®, dissolved in 1 cup water. Protein and 
carbohydrate treatments were isocaloric. 
Exercise protocol. Each trial began with the fasted subjects arriving at the HMU in the early 
morning (0 hours). Researchers recorded measurements of height, weight, blood pressure, 
and heart rate, and a phlebotomist drew an 8.5 mL blood sample by venipuncture 
(vacutainer). Each subject recorded his initial muscle soreness, performed a short muscle 
strength test on the dynamometer identical to the screening test, and completed a level of 
exertion evaluation. Perceived muscle soreness was assessed using a continuous-range 
evaluation. The subjects self-reported their soreness on a scale from 0-10 (0 representing “not 
at all sore” and 10 representing “extremely sore”). Perceived level of exertion was assessed 
using a continuous-range evaluation. The subjects self-reported their soreness on a scale from 
0-10 cm (0 representing “no exertion” and 10 representing “maximum exertion”). The 
purpose of this evaluation was to encourage subjects to exert maximal exertion and to 
compare exertion levels between trials. 
The subject performed the muscle-damaging eccentric exercise protocol, consisting of 
extending and contracting the right leg against a controlled force provided by the 
dynamometer. The dynamometer was set in passive mode and thus did not move without 
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force placed against it. Subjects were encouraged to perform maximal voluntary effort during 
all sets, performing 10 sets of 10 repetitions of leg extensions at 60 deg/s at 120% of 
maximum peak torque recorded during the screening muscle strength test. A one-minute 
break occurred between all intervals, and the entire protocol lasted about 15 minutes. After 
the first and last exercise intervals, the subject completed an evaluation of his level of 
exertion. Immediately following the exercise protocol, the subject drank a beverage, either 
protein, carbohydrate, or placebo. The subject then completed another evaluation of his 
muscle soreness and provided another 8.5 mL blood sample. Thirty minutes after exercising, 
each subject had his blood pressure and heart rate taken. The subject was then allowed to 
leave the unit but was asked to refrain from eating any food until at least 45 minutes after the 
completion of exercise. Water was provided ad libitum throughout the protocol. 
Subjects returned to the HMU in a fasted state the following two days (24 and 48 
hours), at approximately the same assigned time as the first day. Weight, blood pressure, and 
heart rate were recorded, and an 8.5 mL blood sample was taken. Each subject completed 
another muscle strength test, an evaluation of level of exertion, and an adverse events 
questionnaire. Muscle soreness evaluations were completed before and after the strength test.  
At least two weeks after the first trial, each subject returned and repeated the exact 
same protocol, except he consumed a different treatment beverage. At least two weeks later, 
each subject again returned, and ingested the third beverage option. During the three days 
before the second and third trials, each subject was asked to consume the identical diet he 
consumed during the first trial period. 
Analysis of Records 
 All 24-hour diet records were analyzed using Nutritionist Pro™ (Axxya Systems; 
Stafford, TX). All 24-hour physical activity records were analyzed by quantifying subjects’ 
daily activities (METs) as rest, light activity, moderate activity, or heavy activity. These 
category distinctions were based on standard lists of various activities (Ainsworth et al. 
1993). 
Analysis of Blood Samples 
Phlebotomists collected blood samples from fasted (10 hours) participants between 
6:00 and 8:30 a.m. We separated plasma from whole blood by centrifuging for 10 minutes 
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(room temperature) at 1500 x g and stored aliquots at -80oC until analyses. Initial blood 
samples were analyzed by a certified clinical laboratory (LabCorp; Kansas City, Kansas) for 
a complete blood count (CBC) with differential and general chemistry panel (ChemScreen). 
We determined plasma CPK activity in duplicate using a Creatine Kinase Reagent Set 
(Pointe Scientific, Inc.; Canton, MI), according to the manufacturer’s instruction. The 
absorbance of the samples was determined on a Beckman spectrophotometer (Beckman 
Coulter, Inc.; Fullerton, CA) and compared to standards provided by the company. The 
spectrophotometer measured the rate of NADH formation (measured at 340 nm), directly 
proportional to serum CPK activity, as illustrated below: 
 
    CPK 
ADP + Creatine Phosphate ÆÆÆÆÆ Creatine + ATP 
 
  Hexose Kinase 
ATP + Glucose ÆÆÆÆÆÆ ADP + Glucose-6-Phosphate 
 
     G6PDH* 
Glucose-6-Phosphate + NAD+ ÆÆÆÆÆÆÆ 6-Phosphogluconate + NADH + H+ 
*glucose-6-phosphate dehydrogenase 
 
Statistical Analysis 
Statistical analyses were performed using SAS (version 9.1; Cary, NC), with results 
considered statistically significant at p≤0.05. Descriptive statistics included means for 
normally distributed data (height, weight, level of exertion, dietary values, physical activity 
values, and muscle strength values) and medians for data that were not normally distributed 
(CPK and muscle soreness). To determine whether day, trial, or treatment exerted an effect 
on CPK or muscle soreness, analysis of variance (ANOVA) was used. We used a mixed 
model, with fixed effects for day, trial, and treatment, with incorporation of a random effect 
for subject. 
 
RESULTS 
Initial subject characteristics are reported in Table 1. All subjects met the inclusion 
and exclusion criteria of the study. Subjects included 21 healthy, young (20 – 28 years) males 
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with BMI ranging from 19.8 to 29.9. An important goal of the study was to maintain similar 
circumstances throughout all trials to minimize potential confounding from various 
extraneous factors. Thus, each subject was asked to maintain a similar dietary intake and 
physical activity level prior to each trial, as well as identical eccentric exertion during all 
three trials. At baseline, the ANOVA revealed no statistical difference among the treatments 
(protein, carbohydrate, placebo) for subject characteristics/activities (Table 2). 
ANOVA was performed with data categorized by day (0, 24, or 48 hours) of the trial, 
trial number, and treatment type. The main indices of muscle damage after the eccentric 
exercise protocol were CPK (U/L) and subjective muscle soreness evaluations (0-10 cm 
scale), although we also assessed exercise measures of strength from the Biodex. It was clear 
that the eccentric exercise protocol caused muscle damage (Figures 1 and 2). The ANOVA 
for overall day effect revealed significant differences for CPK (p≤0.0001) and muscle 
soreness (p≤0.0001), as well as 6 (p ranged from 0.007 to 0.034) of 8 muscle strength tests, 
with smaller values for muscle soreness on day 1 than day 2 or 3. Clearly, the eccentric 
exercise effectively achieved muscle damage. In examining the overall trial effect, we noted 
several significant differences among trials. The ANOVA for overall trial effect showed 
significant differences for muscle soreness (p≤0.0001) and for 6 (p ranged from ≤0.0001 to 
0.017) of 8 exercise muscle strength tests. Specifically, greater muscle damage occurred 
during trial 1 than during trial 2 or 3, as evidenced by statistically significant differences in 
muscle soreness values between trials 1 and 2 (p≤0.0001) and between trials 2 and 3 
(p=0.0002), as well as greater CPK values (p=0.039) and several muscle strength indices in 
trial 2 compared with 1. We analyzed CPK activity and muscle soreness evaluation by 
treatment type, as depicted graphically (Figures 1 and 2). However, examining the overall 
treatment effect, we documented no significant differences as indicated by either CPK or 
muscle soreness values. Thus, the eccentric exercise protocol produced significant muscle 
damage with a documented trial effect, but treatment type had no effect on muscle soreness 
or recovery. 
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DISCUSSION 
 Contrary to other studies (Sugita et al. 2003; Ohtani et al. 2006), the results of this 
study indicated no significant effect of treatment on muscle damage, soreness, or recovery 
after moderate eccentric exercise (Figures 1 and 2). However, similar to previous studies 
(Gleeson et al. 1995; Newham et al. 1983b; Chapman et al. 2006; Vincent et al. 1997; 
Paschalis et al. 2005b), the eccentric exercise protocol successfully induced muscle damage, 
as evidenced by increased CPK activity and perceived muscle soreness values between day 1 
and days 2 and 3 of sequential trials. Also, not surprisingly as previously explained (Byrnes 
et al. 1985), we documented a trial effect, with significantly greater muscle damage during 
and after trial 1 compared with trials 2 or 3. 
Although several studies (Sugita et al. 2003; Ohtani et al. 2006; Flakoll et al. 2004; 
Wojcik et al. 2001; Millard-Stafford et al. 2005) indicated that protein and/or carbohydrate 
supplements after eccentric exercise decreased muscle damage compared with placebo, some 
authors (Kreider et al. 1993; Williams 1999) remain skeptical that protein and/or 
carbohydrate supplements cause increased muscle recovery. Several possible factors may 
explain why our data did not indicate significantly decreased muscle damage after protein 
and/or carbohydrate supplement intake. 
Perhaps the main reason we did not document a treatment effect was because our 
exercise protocol induced moderate, not severe, muscle damage. Our objective was to create 
muscle damage similar to that of “real life”; it was not our goal to design an exercise protocol 
that would induce excruciating pain caused by muscle damage. Our aim was to determine 
whether a protein supplement would increase muscle recovery subsequent to a realistic 
exercise protocol. Thus, we chose to cause mild muscle damage using right leg eccentric 
exercise on a dynamometer, with a protocol similar to recently published studies (Paschalis 
2005a; Babul et al. 2003). Other studies using alternative eccentric exercise protocols created 
more severe muscle damage, indicated by CPK activity as high as 1500 U/L from downhill 
walking (Newham et al. 1986) or as high as 34,500 IU/L from eccentric stepping (Newham 
et al. 1983a). Although this severe damage may have produced an effect in response to 
treatment, our aim was not to determine the response to protein by inducing severe pain or 
muscle damage. 
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Another possible explanation for the lack of treatment effect may be the small dose 
size provided to the well-nourished subjects in this study. Because our objective was to 
conduct a realistic study applicable in practical situations, we chose to administer 0.4 g 
protein/kg body mass. It is unlikely that our participants’ diets were lacking in either energy 
or protein, as evidenced by their reported energy (~7934 kJ/d) and protein (78 – 83 g/d) 
intake from their three day, 24-hour diet records. If anything, these values are an 
underestimate of energy intake, given that study participants typically underreport dietary 
intake (Jonnalagadda et al. 2000). One would expect that in well-nourished individuals, the 
extracellular pool of amino acids would not be particularly limiting, except perhaps after a 
long-term fast (Bohe et al. 2003). Hence, a relatively small amount of protein supplements 
may not exert a sufficient effect on extracellular amino acid concentrations and thus 
influence intracellular protein synthesis subsequent to moderate muscle damage. The dose 
administered in research studies (Williams et al. 2003; Wojcik et al. 2001; Berardi et al. 
2006) varies greatly, but it is commonly ~1.0 g protein/kg body weight. However, studies 
often administer much larger doses. A recent study (Nosaka et al. 2006) compared the effect 
of ingesting various doses of a protein supplement on exercise-induced muscle damage. 
Before and after endurance exercise using the elbow flexors, subjects ingested a total of 
either two or ten doses of protein supplement. The subjects who consumed only two protein 
doses versus placebo reported no significant difference in CPK activity or muscle soreness, 
but the subjects who consumed ten protein doses verses placebo showed significantly lower 
CPK activity and muscle soreness. Clearly, the greater but not lesser amount of protein in 
supplement form had a significant effect on muscle recovery after exercise. 
 This study had several limitations in that the participants were self-selected, 20 – 28 
year old, well-nourished, healthy male volunteers. Hence, the results may not be applicable 
to the entire male population, and conclusions from the data cannot be drawn for females. 
Another limitation was that the subjects were free-living men, and thus we could not monitor 
the subjects’ physical activity or dietary intake. Although subjects were instructed to refrain 
from physical activity for one week before each trial, their actual physical activity was not 
quantified. Thus, their usual physical activity may have had an undeterminable effect on 
muscle soreness and CPK activity. Although each subject was instructed to repeat his three 
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day recorded dietary intake from to the first trial during the second and third trials, this did 
not occur in practice in a majority of the subjects. Also, the exercise bouts were performed on 
a Biodex machine, which uses a person’s own resistance to determine his/her level of power 
output. Although subjects were strongly encouraged to work “as hard as they can”, the work 
performed from subject to subject undoubtedly varied. However, because each subject served 
as his own control, this should not have confounded the overall results, as long as each 
subject performed similarly from trial to trial. In addition, we evaluated a relatively small 
number (N=21) of subjects, although similar studies (Zainuddin et al. 2006; Paschalis et al. 
2005b; Eston et al. 1996; Nelson et al. 2004) indicated a response to treatment, with subject 
numbers ranging from 5 to 20. However, a trial with a greater number of subjects would 
provide greater statistical power for detecting small changes, which may not have been 
detectable because of inherent inter-individual variability. 
 
CONCLUSION 
 In conclusion, a protein or carbohydrate supplement consumed after moderate 
eccentric exercise did not significantly affect muscle damage or recovery. Further research is 
needed to determine whether significant changes may be realized with greater muscle 
damage, larger dose sizes, or with a different sample of subjects. 
 
ACKNOWLEDGEMENTS 
 The authors would like to sincerely thank the 21 participants in this study for their 
cooperation and interest in this research. We would also like to thank Metabolic 
Technologies, Inc. for loaning us their Biodex Isokinetic Dynamometer for use in this study. 
Finally, thank you to Center for Designing Foods to Improve Nutrition and Iowa State 
University for supporting this research and providing funding to complete this project. 
 
 
 
 
 
  
34
Table 1. Subject Characteristics at Baseline 
 Mean ± SD Range 
Age (years) 23 ± 2 20 – 28 
Weight (kg) 79.2 ± 10.1 63.7 – 98.2 
Height (cm) 179.6 ± 5.4 170.1 – 191.2 
Body Mass Index (kg/m2) 24.6 ± 3.0 19.8 – 29.9 
Fat Free Mass (kg) 63.7 ± 5.3 53.9 – 73.4 
Fat Free Mass (% mass) 80.1 ± 4.0 72.0 – 88.5 
Fat Mass (kg) 16.2 ± 5.0 8.4 – 27.1 
Fat Mass (% mass) 19.9 ± 4.0 11.5 – 28.0 
 
 
 
 
 
 
Table 2. Dietary Intake1 of Subjects at Baseline According to Treatment 
 
1 Does not include protein or carbohydrate supplement intake 
2ANOVA indicated that there were no significant differences among treatment groups. 
 
 
 
 
 
 Treatment Group   
 Potential Confounding Factors Placebo Protein Carbohydrate  
Comparison 
Among 
Groups2 
  Mean ± SD Mean ± SD Mean ± SD  p-value 
Energy (kJ/day) 7934 + 1800 8093 + 1775 8273 + 2403  0.86 
Protein (g/day) 78 + 17 75 + 17 83 + 21  0.41 
Carbohydrate (g/day) 236 + 66 244 + 56 248 + 92  0.87 
Fat (g/day) 73 + 26 74 + 36 81 + 27  0.66 
  
35
Figure 1. Serum CPK Activity (U/L) According to Treatment 
Day Treatment1 Min 25th quartile 50th quartile 75th quartile Max 
1 Placebo 40 101 150 173 479 
1 Protein 46 95 138 170 463 
1 Carbohydrate 53 112 131 158 290 
2 Placebo 103 159 251 391 924 
2 Protein 86 184 229 394 836 
2 Carbohydrate 111 180 228 258 1172 
3 Placebo 92 139 214 325 2241 
3 Protein 57 120 160 359 572 
3 Carbohydrate 93 131 194 314 844 
 
1ANOVA indicated that there was no significant difference in CPK activity among the three 
treatment groups. 
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Figure 2. Muscle Soreness Evaluations (0-10 cm scale) According to Treatment 
 
Day Treatment1 Min 25th quartile 50th quartile 75th quartile Max 
1 Placebo 0 0.2 0.4 1.3 4.6 
1 Protein 0 0.4 1 1.6 2.3 
1 Carbohydrate 0 0.4 1.1 1.6 2.7 
2 Placebo 1.2 2.4 3.9 5.8 8 
2 Protein 0.9 2.3 2.9 5.6 7 
2 Carbohydrate 0.8 2 3.1 5.4 9.3 
3 Placebo 1 2.7 4.4 6.2 8.7 
3 Protein 0 1.8 3 6.3 9.9 
3 Carbohydrate 1.7 2.3 3.4 4.8 8.7 
 
1ANOVA indicated that there was no significant difference in muscle soreness among the 
three treatment groups. 
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CHAPTER IV:  GENERAL CONCLUSIONS 
 
In conclusion, a protein or carbohydrate supplement consumed after moderate 
eccentric exercise did not significantly affect muscle damage or recovery. Further research is 
needed to determine whether significant changes may be realized with greater muscle 
damage, larger dose sizes, or with a different sample of subjects. 
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APPENDIX A:  INFORMED CONSENT DOCUMENT 
 
Title of Study:  Impact of Protein Supplementation on Muscle Recovery after Exercise-
Induced Muscle Soreness 
Investigators:  Elizabeth C. Dahlstrom, D. Lee Alekel, PhD, Rick Sharp, PhD,  
 Shawn Baier, MS 
 
This is a research study.  Please take your time in deciding if you would like to participate.  
Please feel free to ask questions at any time. 
 
INTRODUCTION 
 
The purpose of this study is to determine how nutrition affects muscle soreness due to 
exercise and muscle recovery. This study will demonstrate whether a difference in muscle 
soreness and recovery occurs when a person consumes either a protein, energy, or placebo 
supplement after exercise-induced muscle soreness. Increased muscle recovery is a desirable 
and beneficial situation, and therefore this study hopes to demonstrate that a protein or 
energy supplement increases muscle recovery. You are being invited to participate in this 
study because you are a healthy 18 – 30 year old male and able to exercise. 
 
DESCRIPTION OF PROCEDURES 
 
If you agree to participate in this study, the study will last for about 2 months and involve 
three 3-day trial periods. This study will involve 9 visits to the Human Metabolic Unit 
(HMU) in the Human Nutritional Sciences Building on the Iowa State University campus.  
You will receive a one-page outline of the study procedures attached to this form.  During the 
study you may expect the following: 
 
You will be screened as a potential participant prior to enrollment in the study. Screening 
includes the following: height, weight, vital signs (blood pressure and heart rate), and a 
medical history questionnaire. You will also participate in a short training session on the 
exercise machine that will be used in this study.  
 
During this training session, you will sit on an exercise machine and perform a leg 
flexion/extension test. This will consist of extending and contracting your leg about 10 times 
at a pace that is comfortable to you. This training session will allow you to experience what 
the machine feels like and prepare you for the actual experiment. 
 
Also at this time, your diet will be discussed. You will consume the same diet during each of 
the 3-day trial periods. Specific food choices will be left largely up to you, except you will be 
asked to limit alcoholic beverages to two drinks per day while you are recording your dietary 
intake. Also, you will be asked not to consume any alcohol during each of the 3-day trials. 
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Once these screening tests are completed and you meet the entrance criteria, you will be 
asked to participate in the study. Specific dates and times will be arranged according to your 
schedule for trial visits. 
 
You will begin the trial by keeping a written record of your diet starting three days before 
you visit the HMU.  This record will continue until you first visit the HMU for the first 3-day 
trial. You will record your physical activity beginning one day before your first visit to the 
HMU. 
 
You will come to the HMU on the following day (time = 0 hours) in the morning, after an 
overnight fast. You will give a small blood sample (less than two tablespoons), have 
measurements of height, weight, vital signs, and body composition, and fill out a written 
muscle soreness evaluation.  
 
Body composition will be assessed by bio-electrical impedance analysis (BIA). With BIA, 
two electrodes are attached to the foot and two electrodes are attached to the hand. By 
measuring the small electrical field created between these electrodes, body composition (fat 
and lean tissue) is estimated from the body’s resistance to this field. 
 
You will then be instructed to perform a leg flexion/extension test which will exercise your 
right leg muscles to induce muscle soreness. This test consists of extending and contracting 
your right leg against a controlled force for ten one-minute intervals, with a one minute break 
between intervals. After each exercise interval, you will fill out a written level of exertion 
evaluation. Immediately following the exercise, you will drink a beverage containing either 
protein, carbohydrate, or a placebo. You will then give another small blood sample (less than 
two tablespoons). You will then be asked to fill out another written muscle soreness 
evaluation. Thirty minutes after exercising, your vital signs will be taken again.  You will be 
allowed to leave, and we will provide you with bottled water.  However, we ask that you 
refrain from eating any food until at least 60 minutes after the completion of exercise. 
 
You will return to the HMU on the following day (time = 24 hours) at approximately the 
same assigned time as the first day.  This will be in the morning after an overnight fast. You 
will again give a small blood sample (less than two tablespoons) and your weight and vital 
signs will be measured. You will fill out a muscle soreness evaluation and an adverse events 
questionnaire. You will then perform a short leg flexion/extension test to evaluate your leg 
strength. This will require you to extend and contract your leg about 10 times to measure 
muscle strength.  Your muscles will not be worked to induce soreness this time. Following 
this strength test, you will again fill out a level of exertion evaluation, a muscle soreness 
evaluation, and you will be allowed to leave.  
 
You will again return to the HMU on the following day (time = 48 hours) at approximately 
the same assigned time in the morning after an overnight fast. You will again give a small 
blood sample (less than two tablespoons), and your weight and vital signs will be measured. 
You will fill out a muscle soreness evaluation and an adverse events questionnaire. You will 
again perform the same leg flexion/extension test to evaluate your leg strength. Following 
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this strength test, you will again fill out a level of exertion evaluation and a muscle soreness 
evaluation. After these tests, you will stop your physical activity record and the first trial will 
be finished. 
 
Approximately 2 weeks later, you will be asked to come to the HMU again and perform a 
second trial, consisting of the same set of tests from 0 hours to 48 hours. During this trial 
however, you will be given a different beverage to drink.  You will be asked to consume the 
same diet as in the first 3-day trial, at times identical to those in the first 3-day trial. 
 
Approximately 2 weeks after the second trial, you will be asked to come to the HMU again 
and perform a third trial, consisting of the same set of tests from 0 hours to 48 hours. During 
this trial, you will be given a different beverage to drink.  You will be asked to consume the 
same diet as in the first 3-day trial, at times identical to those in the first 3-day trial. 
 
During all surveys and questionnaires, you may skip any question that you do not wish to 
answer or that makes you feel uncomfortable. 
 
 
RISKS 
 
While participating in this study you may experience the following risks:   
 
(a) Bio-electrical impedance analysis to estimate body composition (fat and lean masses) is a 
painless, non-invasive test.  You will be asked to lie still while a technician tapes electrodes 
to your hand and foot.  A very small electrical current will be passed through your body.  
You will not be able to feel the current.  You will be asked not to wear jewelry, hosiery 
(panty hose) or clothing with metal buttons or buckles, as they may interfere with the test.   
The entire procedure lasts about 5 minutes. 
 
(b) The leg flexion and extension test will be conducted on a Biodex exercise machine by 
standard muscle-soreness inducing procedures, which requires the subject to exercise his leg 
using concentric and eccentric exercises. This may result in short-term soreness, but no long-
term injury is expected. Risk of injury from exercise will be minimized by having the subject 
exercise at a pace that is comfortable for him with trained personnel monitoring the exercise 
at all times. 
 
(c) Venipuncture, or blood collection, may be associated with hematoma, local discomfort, 
and on rare occasion, infection.  Standard techniques will be used by a trained phlebotomist 
to minimize these undesirable outcomes.  The total amount of blood collected for each trial 
will be less than 8 tablespoons, and thus will be less than 24 tablespoons for the entire study. 
 
The risks from consuming the beverages are minimal and no greater than the risks of normal 
food consumption.  The beverages consist of food constituents that are commercially 
available. 
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BENEFITS 
 
If you decide to participate in this study there may be no direct benefit to you.  It is hoped 
that the information gained in this study will benefit society by advancing the knowledge of 
how nutrition impacts exercise and muscle soreness. Specifically, it will help determine the 
role of protein and carbohydrate in muscle recovery after exercise. This information will be 
useful to society because it may discover a way to increase the speed of muscle recovery 
after exercise. Also, you will be offered the results of the body composition assessment.  
 
COSTS AND COMPENSATION 
 
You will not bear any costs from participating in this study. You will be compensated for 
participating in this study.  
• You will be compensated $25.00 for each 3-day trial that you complete, with a bonus 
of $25.00 for completing all three trials. If all trials are completed, you will receive a 
total of $100.00. 
 
PARTICIPANT RIGHTS 
 
Your participation in this study is completely voluntary and you may refuse to participate or 
leave the study at any time.  If you decide not to participate in the study or leave the study 
early, it will not result in any penalty or loss of benefits to which you are otherwise entitled.  
 
RESEARCH INJURY 
 
Emergency treatment of any injuries that may occur as a direct result of participation in this 
research is available at the Iowa State University Thomas B. Thielen Student Health Center, 
and/or referred to Mary Greeley Medical Center or another physician or medical facility at 
the location of the research activity.  Compensation for any injuries will be paid if it is 
determined under the Iowa Tort Claims Act, Chapter 669 Iowa Code.  Claims for 
compensation should be submitted on approved forms to the State Appeals Board and are 
available from the Iowa State University Office of Risk Management and Insurance. 
 
CONFIDENTIALITY 
 
Records identifying participants will be kept confidential to the extent permitted by 
applicable laws and regulations and will not be made publicly available.  However, federal 
government regulatory agencies [e.g., FDA] and the Institutional Review Board (a committee 
that reviews and approves human subject research studies) may inspect and/or copy your 
records for quality assurance and data analysis.  These records may contain private 
information.   
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To ensure confidentiality to the extent permitted by law, the following measures will be 
taken  
• Subjects will be assigned a unique subject number, which will be used on files instead 
of their name. 
• Identifiers will be kept with the data. 
• Only the principal investigator and assistants will have access to study records and 
identification codes, which will be kept in a locked office in a filing cabinet as well as 
on a password protected computer file. 
• Data will be retained until approximately the end of 2008. 
• If the results are published, your identity will remain confidential. 
 
QUESTIONS OR PROBLEMS 
 
You are encouraged to ask questions at any time during this study.   
 
• For further information about the study contact Elizabeth Dahlstrom (515-294-3932), 
Dr. Rick Sharp (515-294-8650), or Dr. D. Lee Alekel at (515-294-3552). 
• If you have any questions about the rights of research subjects or research-related 
injury, please contact Ginny Austin Eason, IRB Administrator, (515) 294-4566, 
austingr@iastate.edu, or Diane Ament, Research Compliance Officer (515) 294-3115, 
dament@iastate.edu.  
 
*************************************************************************** 
SUBJECT SIGNATURE 
 
Your signature indicates that you voluntarily agree to participate in this study, that the study 
has been explained to you, that you have been given the time to read the document and that 
your questions have been satisfactorily answered.  You will receive a copy of the signed and 
dated written informed consent upon request. 
 
Subject’s Name (printed)               
    
             
(Subject’s Signature)      (Date)  
 
INVESTIGATOR STATEMENT 
 
I certify that the participant has been given adequate time to read and learn about the study 
and all of their questions have been answered.  It is my opinion that the participant 
understands the purpose, risks, benefits and the procedures that will be followed in this study 
and has voluntarily agreed to participate.    
 
             
(Signature of Person Obtaining    (Date) 
Informed Consent) 
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APPENDIX B:  MEDICAL HISTORY/PHYSICAL ACTIVITY QUESTIONNAIRE 
  
Medical History Form 
 
STUDY: Impact of Protein Supplementation on Muscle Recovery after Exercise-Induced Muscle 
Soreness 
 
Subject Name:_______________________________Date:__________    
Subject ID Number: ________ 
Home Address: _______________________________________________ 
Street 
_______________________________________________ 
City State  Zip 
Home Phone:_______________________ 
 
  
Emergency Information: 
 
Personal Physician: _____________________________________________ 
 
Contact in case of  
Emergency: __________________________________________________ 
 
Relationship: _______________________  Phone: ____________________ 
 
Personal Information: 
 
Age:_______  Date of Birth_____/_____/_____ 
Mo.     Day     Year 
 
Sex:   ___ male                                                             Race: ___ White 
 ___female       ___ African American 
___ Asian 
 Ethnic Background: ___ Hispanic/Latino   ___Native Hawaiian/ 
    ___ Not Hispanic/Latino          Pacific Islander 
___American Indian/ 
               Alaska Native 
Highest Level of Education: 
___Elementary  ___Jr. High School  ___High School  ___College  ___Post College 
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Overall Health:_____________________________________________________ 
1. How would you rate your present health condition? 
 ____Poor   ____Fair   ____Good   ____Excellent 
 
2. Typically, how many days per year are you sick enough to stay in bed? ________ 
 
3. Has your weight changed more than 10 lbs. in the last 12 months? __Yes  __No 
 
4. Have you ever smoked? 
 ___Never   ___Not now, but more than 12 months ago   
___Not now, but within the past 12 months   ___Yes, currently smoking 
 
5. Have you ever used any tobacco product on a regular basis?___ yes___ no 
If yes, what product did you use and for how long?  
Product: ___________________________________ Years: ______ 
 
Family Health History________________________________________________ 
Date of Last Physical Exam:        ____/____/____ 
 
A. If any members of your immediate family have or have had any of the following 
conditions, indicate their age at the time of the event: 
Father  Mother Brother(s) Sister(s) 
Heart Attack                       _____ yr        _____ yr        _____ yr _____ yr 
Stroke    _____ yr _____ yr _____ yr _____ yr 
Coronary Artery Disease    _____ yr       _____ yr        _____ yr _____ yr 
If deceased, age at death   _____ yr       _____ yr        _____ yr _____ yr 
 
B. Indicate if any members of your immediate family have or have had the following 
conditions by marking the appropriate lines: 
Father  Mother Brother(s) Sister(s) 
High Blood Pressure        _____ yr        _____ yr          _____ yr _____ yr 
High Cholesterol              _____ yr         _____ yr         _____ yr _____ yr 
Diabetes                          _____ yr         _____ yr         _____ yr _____ yr 
Obesity                            _____ yr         _____ yr         _____ yr _____ yr 
 
Personal Medical History______________________________________________ 
Answer the following questions, indicating the month and year of the event or diagnosis 
where appropriate. 
Yes     No Mo/Yr 
1.  Has a doctor ever told you that you have heart disease?    ___    ___    ___/___ 
2.  Have you ever had a heart attack?                                      ___    ___ ___/___ 
3.  Have you ever had chest pain?                                            ___    ___ ___/___ 
4. Do you have a cardiac pacemaker?                                      ___  ___    ___/___ 
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5. Has your doctor ever told you that you have 
a heart valve problem?       ___  ___   ___/___ 
6. Have you had a heart valve replacement surgery?               ___     ___   ___/___ 
If yes, what heart valve was replaced? 
  __ mitral   __ aortic 
 
7.  Have you ever had any sort of heart surgery?   ___  ___ ___/___ 
   
If yes, what type of surgery?______________________________________ 
 
8. Have you had cardiomyopathy?                                            ___    ___ ___/___ 
9. Have you had a heart aneurysm?                                         ___     ___ ___/___ 
10. Have you had heart failure?                                                ___  ___ ___/___ 
11.  Do you have hypertension (high blood pressure)?            ___     ___ ___/___ 
12. Have you ever had a stroke?                                              ___     ___    ___/___ 
13. Do you have diabetes mellitus?                                          ___     ___ ___/___ 
14. Have you ever had respiratory problems?   ___ ___ ___/___ 
15. Have you ever been diagnosed with asthma?  ___ ___ ___/___ 
 If yes, is the condition controlled?    ___ ___ ___/___ 
 
16. Have you ever had or been told you have any other medical problems? 
 (Ex. knee problems, allergies, anemia, liver disease, kidney disease, etc.) 
 
If yes, please explain:  
 
________________________________________________________________ 
 
________________________________________________________________ 
 
________________________________________________________________ 
 
17.  Has your doctor ever told you not to exercise for any reason? 
  Yes ___ No ___ 
  
If yes, please explain:  
 
________________________________________________________________ 
  
18. Have you ever had surgical procedures? (Ex. tonsillectomy, kidney surgery, etc.)  
 
If yes, please explain, and include date of surgery:  
 
________________________________________________________________ 
 
________________________________________________________________ 
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19. Medications:  
 
List medications you are taking currently or take on a regular basis: 
 
Name of drug                   Times/day         Dosage (mg)       Duration of use 
 
___________________    _________        ________        _____________ 
 
___________________    _________        ________        _____________ 
 
___________________    _________        ________        _____________ 
 
___________________    _________        ________        _____________ 
 
___________________    _________        ________        _____________ 
 
 
 
 Physical Activity 
 
1. What would you consider your current physical activity level to be? Please circle the most 
representative choice. 
    
 Heavy   Moderate      Light        None 
  
2. Are you currently on a physical activity program?     Yes    No 
 
  If yes, what program? __________________________________ 
 
 
3. List physical activities that you normally do each week, including both cardiovascular and 
resistance exercises: 
 
Activity                                Duration       Times/week    Intensity 
 
Ex. Walking___________   30 min___    ___3____ Moderate 
 
___________________      _________   ________ ________ 
 
___________________      _________   ________ ________ 
 
___________________      _________   ________ ________ 
 
___________________      _________   ________ ________ 
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4. Do you plan on starting a new physical activity program anytime in the next 2 months?  
  Yes No 
 
   If yes, what program do you intend to start? ____________________________ 
 
 
Statement of Confidentiality 
I understand that the information contained on this questionnaire is regarded as 
confidential,  and will not be released without my prior written permission.  The 
research center may, however, use the information for statistical and other research 
purposes. 
 
 
Signature _________________________________________ Date ___/___/___ 
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APPENDIX C: 
MUSCLE SORENESS EVALUATION 
 
Study: Impact of Protein Supplementation on Muscle Recovery after Exercise-Induced Muscle 
Damage 
 
Subject Identification Number_______ 
Date______ 
Time______ 
 
 
Muscle Soreness Evaluation 
 
 
Below is a line representing a gradual scale of muscle soreness. Please mark a 
vertical line on the part of the scale that best represents how sore your right leg 
muscles feel at this moment: 
 
 
 
 
 
 
_________________________________________  
    Not at all                   Extremely         
        Sore                                      Sore 
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LEVEL OF EXERTION QUESTIONNAIRE 
 
 
 
Study: Impact of Protein Supplementation on Muscle Recovery after Exercise-Induced Muscle 
Damage 
 
Subject Identification Number_______ 
Date______ 
Time______ 
 
 
Level of Exertion Questionnaire 
 
 
Below is a line representing a gradual scale of your level of exertion. Please 
mark a vertical line on the part of the scale that best represents your level of 
exertion on the trial you just finished: 
 
 
 
 
 
 
________________________________________ 
        
     No                   Maximum 
 Exertion                  Exertion 
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ADVERSE EVENTS HEALTH FORM 
 
 
Adverse Events Health Form 
 
STUDY: Impact of Protein Supplementation on Muscle Recovery after Exercise-Induced 
Muscle Soreness         
 
Subject ID                        NAME: _____________________________ 
 
 
 
 
 
 
 
Day 2 of trial, DATE: _____-____-_____ 
 
 
Have you had any adverse events in the last 24 hours? (circle) 
 
  Yes  No 
 
If yes, what were the events?________________________________________________ 
 
What action did you take?__________________________________________________ 
 
What is the outcome (resolved, still present, etc.)?______________________________ 
 
 
 
 
Day 3 of trial, DATE: _____-____-_____ 
 
 
Have you had any adverse events in the last 24 hours? (circle) 
 
  Yes  No 
 
If yes, what were the events?________________________________________________ 
 
What action did you take?__________________________________________________ 
 
What is the outcome (resolved, still present, etc.)?______________________________ 
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APPENDIX D:  RAW DATA 
Table 1. Subject Height, Weight, and CPK Activity Data 
Subject # Trial Treatment Height (cm) Weight (kg) CPK activity (U/L) 
      Day 1 Day 1 Day 2 Day 3 0 hours 0.5 hours 24 hours 48 hours
                   
ED402 1 Protein 178 74.5 71.8 71.9 52.4 58 229.4 159.9 
ED402 2 Carbohydrate 178.3 72.4 72.8 72.8 76.1 72 178.6 105.8 
ED402 3 Placebo 177.9 72.5 72.4 71.7 75.1 87.5 136.6 139.4 
             
ED404 1 Carbohydrate 186.8 83.2 83.5 83.9 210.8 231.4 455.7 315.6 
ED404 2 Placebo 186.7 82.5 82.2 82.7 178.3 181.1 526.4 324.3 
ED404 3 Protein 187.2 82.2 81.7 80.9 149.5 NA 258.4 333.1 
             
ED405 1 Carbohydrate 186.5 80 79.9 79.9 122.1 112.2 223.3 315.8 
ED405 2 Placebo 186.7 78.5 79.1 78.9 77.5 79.3 102.8 91.5 
ED405 3 Protein 187 78.2 77.5 78 199.2 231.7 203.2 119.3 
             
ED406 1 Protein 181.3 83.8 83 82.6 148.2 169.1 486 20177.1
ED406 2 Carbohydrate 181.4 82.8 83 83.8 233 245.2 249.3 531.2 
ED406 3 Placebo 181 84.4 85.1 85.2 197.3 196.1 279.3 263.8 
             
ED407 1 Carbohydrate 176.8 75.9 76.1 76.7 72.5 60.3 250.5 143.7 
ED407 2 Placebo 176.3 78.7 79 78.7 178 185.1 271.3 221.5 
ED407 3 Protein 176 78.7 77.9 79.1 72.3 79.3 189.2 126.2 
             
ED409 1 Placebo 174.5 84.5 85 84.6 168.8 176.5 923.5 758.9 
ED409 2 Carbohydrate 175.7 85.5 84.3 85 289.9 286.3 1171.6 844.3 
ED409 3 Protein 175.3 86.1 86.2 87.1 463.4 477.6 814.8 436.7 
             
ED410 1 Placebo 180 71.5 70.9 71.8 66.6 75.5 169.4 122.4 
ED410 2 Protein 180.2 69.9 70.2 70.4 64.4 68.9 192 124.3 
ED410 3 Carbohydrate 179.6 68.7 70.9 70.8 131.2 151.3 115.5 119.5 
             
ED411 1 Placebo 176.9 94.4 92.8 92.8 109.8 114.2 138.3 2241.3 
ED411 2 Protein 177 93.6 93.7 93.1 73.3 71.4 85.5 78.8 
ED411 3 Carbohydrate 177.5 92.8 93.3 94.3 69.4 70.4 179.5 733.2 
             
ED412 1 Carbohydrate 184.5 78.4 76.9 77.2 123.8 120.3 188 159.4 
ED412 2 Protein 185 79.9 79 79 160.2 159.2 240.4 246.2 
ED412 3 Placebo 184 75.6 75.4 74.8 84 85.9 117.8 95.3 
             
ED413 1 Placebo 180.6 96.8 95.6 95.7 112.4 117.7 160.7 137.6 
ED413 2 Protein 179.8 96.5 95.4 95.1 100.9 100.7 92.1 96.9 
ED413 3 Carbohydrate 179.6 96 96 94.5 118 128.2 111.1 106.8 
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Table 1. Subject Height, Weight, and CPK Activity Data (continued) 
Subject # Trial Treatment Height (cm) Weight (kg) CPK activity (U/L) 
   Day 1 Day 1 Day 2 Day 3 0 hours 0.5 hours 24 hours 48 hours
ED414 1 Placebo 184.5 94.7 94.5 95.2 158.5 166 390.1 255.9 
ED414 2 Carbohydrate 186.4 93.4 93.2 94 136.3 NA 257.7 194 
ED414 3 Protein 184.5 92 91.6 91.9 174.2 172.9 388.9 229.4 
                      
ED416 1 Protein 176 77.2 77.4 77.3 279.5 316.9 590 384.3 
ED416 2 Carbohydrate 175.9 76.8 75.7 76.3 138.9 NA 434.6 313.8 
ED416 3 Placebo 176.1 65.4 76.2 76.4 327.3 168.1 391.4 327.3 
                      
ED418 1 Placebo 170.5 62.9 62 62.4 150.1 137.1 826.8 457.8 
ED418 2 Carbohydrate 170.1 62.9 62.6 62.7 158.2 159.9 205.2 130.9 
ED418 3 Protein 170.2 62 61.8 62.5 116 129.5 836.4 490.9 
                      
ED419 1 Placebo 176.5 78.9 78.4 78.1 104 98.9 123.8 108.6 
ED419 2 Protein 176.7 76.9 77.4 77.6 182.8 172.2 190.8 157.9 
ED419 3 Carbohydrate 176.4 77.7 77.9 77.8 140.4 131 181.4 228.9 
                      
ED420 1 Protein 181.5 76.8 76.2 76.7 137.6 147.7 532.1 6737.2 
ED420 2 Carbohydrate 181.6 76.6 77 78.4 239.8 238.8 271.3 224 
ED420 3 Placebo 182.5 76.7 77.6 76.4 162.2 171.3 234.7 207.3 
                      
ED424 1 Placebo 192 73.2 74 74.4 101.4 94.9 158.7 170.4 
ED424 2 Carbohydrate 191 72.8 73.1 72.8 138.8 154.7 240.1 147.3 
ED424 3 Protein 192 72.2 73 72.4 108.6 108.4 287.1 385.8 
                      
ED425 1 Placebo 177 77.1 76.9 77.4 40 41.9 250.5 NA 
ED425 2 Carbohydrate 177.3 78.9 78.8 78.3 53.4 39.9 156.9 111.4 
ED425 3 Protein 178.5 79 79.3 78.9 46 47.6 88.8 56.7 
                      
ED426 1 Placebo 170.9 69 69.4 69.4 107.1 113.9 393.5 939.5 
ED426 2 Carbohydrate 170.9 69 68.5 69 111.9 117.2 239 216.7 
ED426 3 Protein 171.3 68.2 68.9 69 95.3 104 183.9 120.6 
                      
ED427 1 Protein 184 98.9 97.8 98.4 147.8 152.1 393.9 572.4 
ED427 2 Carbohydrate 184.2 99.1 99.3 98 121.3 128.2 228.1 176.2 
ED427 3 Placebo 184 99.8 99.8 99 478.6 469.8 422.2 234.2 
                      
ED428 1 Carbohydrate 184.3 78.5 78.6 78.7 265.2 290.4 283.5 269.6 
ED428 2 Protein 186.1 78.4 78.6 78.2 170 184.1 172.5 174.2 
ED428 3 Placebo 185 79.9 78.9 78.3 165 154.7 278 184.6 
                      
ED429 1 Placebo 170.7 67.2 66.2 66.6 172.5 184.1 224.3 160.4 
ED429 2 Carbohydrate 171.7 65.4 65.7 65.9 111.4 123.1 123.4 92.9 
ED429 3 Protein 171 65.2 64.2 65.4 129.5 137.4 153.6 107.6 
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Table 2. Subject Perceived Muscle Soreness and Level of Exertion Data 
Subject # Trial Treatment Muscle Soreness (0-10 cm scale) 
Level of Exertion (0-10 
cm scale)   
      1 2 3 4 5 6 1 2 3 4 5 
                 
ED402 1 Protein 1.3 4.6 6.7 8.6 6.3 7.3 9.5 8.6 9.6 9.3 9.3 
ED402 2 Carbohydrate 1.2 8.3 3.4 5.9 2.3 2.6 8.2 9.4 9.6 8.8 7.2 
ED402 3 Placebo 3 7 5.1 8.7 5.9 5.3 8 8.7 9 7.3 8.2 
                 
ED404 1 Carbohydrate 0.4 6.5 7.5 9.1 8.7 7.2 8.7 6.5 9.6 1.9 2.5 
ED404 2 Placebo 0.3 0.7 3.2 4.9 3.7 4.7 8.5 7.9 9.1 5.6 5.2 
ED404 3 Protein 0.3 3.5 1.3 3.5 3.7 6.2 4.4 7.4 9.3 4.9 3.7 
                 
ED405 1 Carbohydrate 0.2 7.8 2.7 4.5 3.4 5.7 8.7 8.9 9.2 7.7 7.8 
ED405 2 Placebo 0.4 8.2 1.6 3.8 2.3 4.9 8.7 9.1 9.1 9.4 9.3 
ED405 3 Protein 0.6 8.9 1.8 3 0.9 3.4 8 9 8.8 9.2 9.3 
                 
ED406 1 Protein 1.7 9 5.9 6.5 7.2 6.4 4.4 5.7 8.9 4.2 5.1 
ED406 2 Carbohydrate 1.7 7.3 5.4 6.1 5.7 5.9 3.9 6 7.4 4.9 3.2 
ED406 3 Placebo 1.1 7 3.7 5.8 3.1 5.3 4.6 5.7 6.9 4.9 5.5 
                 
ED407 1 Carbohydrate 1.1 3.2 3.4 4.5 4.8 5 8 7.7 8.1 8.4 8.9 
ED407 2 Placebo 0.4 7.5 1.8 3.8 2.5 3.9 7.8 9.5 9.5 8.7 9.4 
ED407 3 Protein 0.7 7.5 2.7 6.2 2.3 4.1 9.9 8.3 8.3 8.9 9 
                 
ED409 1 Placebo 0.7 10 5 4.8 2.4 2.4 9.8 9.8 9.8 9.8 9.8 
ED409 2 Carbohydrate 0 4.7 2.7 3.7 2 3.1 9.8 9.7 9.8 9.8 9.8 
ED409 3 Protein 1 4.8 2.9 4.3 1.3 1.9 9.8 9.8 9.7 9.7 9.7 
                 
ED410 1 Placebo 0.5 1.9 2.4 2.9 2.7 3.1 6 7.5 8 7.8 8 
ED410 2 Protein 1.8 5.8 2.6 3.1 2.4 2.5 7.8 7.8 7.8 8 6.7 
ED410 3 Carbohydrate 1.5 2.6 1.8 2 2.4 2.5 6.5 7.2 7.5 7.9 7.5 
                 
ED411 1 Placebo 1.5 8.1 5.8 7.2 7.8 8.3 6.9 8.7 8.6 8.2 7.8 
ED411 2 Protein 1.1 5.2 3.2 3.6 2.1 2.2 7.5 9 8.5 8.5 8.7 
ED411 3 Carbohydrate 2.7 7.6 9.3 9.3 8.3 7.6 8.3 8.6 9.3 8.8 9 
                 
ED412 1 Carbohydrate 0.2 7.9 1.4 4.6 1.9 3.9 1.9 3.2 7.9 2.6 4.3 
ED412 2 Protein 0.4 7.8 2.2 3.2 0.7 1 3 3.9 8.2 2.6 2.1 
ED412 3 Placebo 0 6 1.3 3.1 1 1.8 1.9 2.8 8.4 2.1 2.7 
                 
ED413 1 Placebo 0.1 6.2 8 8.2 5.3 2.8 7.1 8 9.1 5.5 6.6 
ED413 2 Protein 1.6 3.6 0.9 2 0 0.6 6.2 7.4 8.7 7.4 7.8 
ED413 3 Carbohydrate 0.1 3.2 2 3.1 1.7 2.1 7.1 8.8 8.5 7.1 9 
 
 
  
62
Table 2. Subject Perceived Muscle Soreness and Level of Exertion Data (continued) 
Subject # Trial Treatment Muscle Soreness (0-10 cm scale) 
Level of Exertion (0-10 cm 
scale)  
      1 2 3 4 5 6 1 2 3 4 5  
ED414 1 Placebo 0 5.4 3.9 6.2 5 7 8.2 8.6 9 8.4 8.3  
ED414 2 Carbohydrate 2.3 5.6 3 4.7 3.7 5.7 8.3 8 8.8 7.9 7.8  
ED414 3 Protein 1.8 5.3 3.4 3.3 1.8 5.4 7.1 7.3 8.4 8 8.4  
                  
ED416 1 Protein 1.4 NA 2.3 4 3 3.9 8 8.3 8.5 8.7 8.7  
ED416 2 Carbohydrate 0.5 7.4 3.6 4.5 3.4 4 8.9 7.7 8.3 8.8 8.5  
ED416 3 Placebo 2.5 2.4 2.4 3.7 3.7 4.4 8.9 8.4 8.5 8.5 8.9  
                  
ED418 1 Placebo 1.2 4.5 7.5 8.5 8.5 6.2 9 9.2 7 8.5 7.7  
ED418 2 Carbohydrate 1.2 5.9 5.7 7.1 4 5.2 8 7.7 9.1 7.8 7.7  
ED418 3 Protein 2.3 5.9 7 8.4 6.4 7 8 8.9 9 8.3 8.3  
                  
ED419 1 Placebo 1.3 2.4 5.8 5.5 6.2 6.9 7.5 6.4 6.5 3.9 5.8  
ED419 2 Protein 1.2 3.7 5.3 5.7 6.1 6.6 7.4 7.6 8.7 6 6.1  
ED419 3 Carbohydrate 1.6 4.1 3.1 4.6 2.9 3.4 6 5.8 6.6 4.8 5.2  
                  
ED420 1 Protein 0.2 6.7 5.6 5.6 9.9 9.6 8.7 8.9 9.7 7.7 9  
ED420 2 Carbohydrate 0.4 0.7 0.8 0.7 1.7 1.6 8.9 9.3 9.5 9.1 9.1  
ED420 3 Placebo 0.4 0.5 1.2 1.1 2 1 9.5 9.3 9.5 9.3 9  
                  
ED424 1 Placebo 0.1 2.6 2.5 3.5 4.7 6.2 7.3 9.4 9.3 7.2 7  
ED424 2 Carbohydrate 0.4 4.9 1.5 1.7 2.9 4.1 7.1 8.6 8.7 7.6 8.5  
ED424 3 Protein 0 4.2 5.8 7.8 7.6 9 7.8 8.6 8.9 9 8.9  
                  
ED425 1 Placebo 0.2 4.8 6.4 7 8.7 9.3 6.4 8.3 9.2 4.1 6.1  
ED425 2 Carbohydrate 0.2 1.6 2 3.5 4 4.4 5.8 6.7 8.8 5.6 5.8  
ED425 3 Protein 0.1 0.3 2.5 2.2 2.4 2.1 5.4 6.5 8.8 6.2 6.4  
                  
ED426 1 Placebo 0.2 6.7 2.8 2.5 3.1 2.7 8.4 8.7 8.5 8.9 8.5  
ED426 2 Carbohydrate 1.2 8.6 2.8 3 2.2 2.4 7.8 8.8 8.9 8.4 9.1  
ED426 3 Protein 0.5 7.1 1.1 0.4 0.5 0.5 9.2 8.8 9.2 9.4 9.5  
                  
ED427 1 Protein 2 4.9 5.6 5 8 6.6 7 8.5 9 8.2 8  
ED427 2 Carbohydrate 1.7 8 5.4 4.3 2.7 1.6 7.6 8 8.1 8.4 9.2  
ED427 3 Placebo 4.6 9 7 6.2 4.4 2.5 7.9 9 8.6 8.6 8.6  
                  
ED428 1 Carbohydrate 0.5 1.6 7.2 5.1 6.2 5.7 8.6 9.5 9.7 8.9 8.9  
ED428 2 Protein 0.2 2.3 6.4 8 4 6.3 8.9 9.5 9.5 8.9 9.5  
ED428 3 Placebo 0.2 3 4.8 5.6 6.5 6.4 9.2 9.1 8.3 9.6 9.5  
ED429 1 Placebo 1.9 6.6 5.3 7 6.8 6.5 6.7 8.4 8.6 6.7 6.6  
ED429 2 Carbohydrate 2.3 7 4.8 4.4 7.9 6.5 7.2 7.8 8.9 7.2 7.9  
ED429 3 Protein 0.5 6.5 2.6 4 3 4.8 6.4 8.5 7.6 6.8 7.1  
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Table 3. Subject Blood Pressure and Heart Rate Data 
Subject # Trial Treatment Blood Pressure (Systolic/Diastolic) Heart Rate (beats/min) 
      0 hr 1 hr 24 hr 48 hr 0 hr 1 hr 24 hr 48 hr 
                      
ED402 1 Protein 129/74 118/77 119/85 115/72 84 73 95 95 
ED402 2 Carbohydrate 128/70 131/78 131/74 120/69 92 71 95 79 
ED402 3 Placebo 124/82 116/82 126/81 113/65 84 68 76 70 
                      
ED404 1 Carbohydrate 126/92 120/82 126/80 126/88 56 96 66 72 
ED404 2 Placebo 125/78 142/81 140/76 134/83 75 80 71 64 
ED404 3 Protein 129/73 139/85 124/80 125/76 66 84 70 65 
                      
ED405 1 Carbohydrate 145/80 138/82 122/73 124/74 84 89 83 74 
ED405 2 Placebo 139/84 127/77 128/77 131/76 85 84 86 84 
ED405 3 Protein 127/72 127/79 126/70 142/78 79 91 71 89 
                      
ED406 1 Protein 118/68 131/85 135/70 123/72 51 60 51 47 
ED406 2 Carbohydrate 124/71 128/81 134/78 123/69 54 55 62 58 
ED406 3 Placebo 117/72 115/71 127/68 122/65 58 55 47 47 
                      
ED407 1 Carbohydrate 143/83 153/86 142/63 141/86 56 60 58 66 
ED407 2 Placebo 143/83 128/48 127/76 133/76 67 62 60 58 
ED407 3 Protein 149/90 137/84 144/82 134/82 76 72 61 58 
                      
ED409 1 Placebo 129/67 135/80 126/69 128/74 65 72 61 67 
ED409 2 Carbohydrate 118/95 135/81 135/61 130/70 64 71 62 68 
ED409 3 Protein 145/65 130/81 126/62 118/67 71 71 69 65 
                      
ED410 1 Placebo 124/65 124/67 104/60 128/64 63 66 73 67 
ED410 2 Protein 125/60 122/64 125/50 114/53 68 58 58 64 
ED410 3 Carbohydrate 120/77 116/69 118/61 110/61 55 51 63 58 
                      
ED411 1 Placebo 158/65 139/63 137/67 120/76 67 64 69 63 
ED411 2 Protein 146/74 141/45 147/79 140/73 62 68 58 67 
ED411 3 Carbohydrate 146/74 157/89 150/77 144/84 67 88 68 68 
                      
ED412 1 Carbohydrate 140/71 146/74 138/68 147/78 54 74 72 72 
ED412 2 Protein 144/71 141/71 136/74 139/65 56 67 64 51 
ED412 3 Placebo 131/107 128/83 143/73 128/82 84 75 83 96 
                      
ED413 1 Placebo 129/76 118/72 138/74 131/71 61 72 71 74 
ED413 2 Protein 116/72 104/67 129/73 130/74 60 61 75 74 
ED413 3 Carbohydrate 130/73 115/89 128/80 124/83 73 71 81 80 
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Table 3. Subject Blood Pressure and Heart Rate Data (continued) 
Subject # Trial Treatment Blood Pressure (Systolic/Diastolic) Heart Rate (beats/min)  
      0 hr 1 hr 24 hr 48 hr 0 hr 1 hr 24 hr 48 hr 
ED414 1 Placebo 140/71 147/72 149/68 134/79 53 47 44 45 
ED414 2 Carbohydrate 134/64 156/82 144/75 129/70 46 64 44 44 
ED414 3 Protein 149/66 122/51 134/75 126/78 50 54 53 52 
                      
ED416 1 Protein 130/77 119/68 114/73 123/59 61 53 50 48 
ED416 2 Carbohydrate 113/64 120/64 122/61 119/61 55 54 62 45 
ED416 3 Placebo 112/66 131/65 118/59 127/65 48 60 45 52 
                      
ED418 1 Placebo 128/67 133/70 130/79 126/69 54 80 80 61 
ED418 2 Carbohydrate 125/68 128/87 80/58 110/58 60 80 66 73 
ED418 3 Protein 118/79 108/76 126/68 131/68 80 76 75 66 
                      
ED419 1 Placebo 126/81 126/81 119/78 130/79 52 54 51 66 
ED419 2 Protein 124/78 122/75 124/80 136/77 50 54 52 46 
ED419 3 Carbohydrate 135/78 132/71 133/76 130/73 60 61 65 79 
                      
ED420 1 Protein 100/61 123/71 131/72 119/68 69 73 73 80 
ED420 2 Carbohydrate 114/79 118/80 137/74 103/63 68 80 85 81 
ED420 3 Placebo 118/63 106/57 105/65 141/69 82 74 58 84 
                      
ED424 1 Placebo 123/64 118/63 104/63 116/64 59 75 64 71 
ED424 2 Carbohydrate 111/65 109/64 118/66 121/70 62 62 57 63 
ED424 3 Protein 115/68 119/70 118/68 122/71 69 79 61 63 
                      
ED425 1 Placebo 144/72 122/66 123/70 125/64 59 57 59 64 
ED425 2 Carbohydrate 135/73 131/78 129/70 136/72 65 73 61 68 
ED425 3 Protein 123/68 113/70 129/67 145/72 66 64 70 69 
                      
ED426 1 Placebo 151/75 127/72 159/94 144/77 76 60 91 73 
ED426 2 Carbohydrate 140/84 123/75 152/91 161/68 76 67 89 78 
ED426 3 Protein 148/86 138/80 154/77 127/74 96 88 79 83 
                      
ED427 1 Protein 145/81 142/82 137/87 130/84 86 83 83 80 
ED427 2 Carbohydrate 140/74 142/77 143/79 157/85 85 79 82 82 
ED427 3 Placebo 149/86 146/94 131/78 144/86 95 93 96 81 
                      
ED428 1 Carbohydrate 131/62 144/70 125/66 111/65 64 73 71 60 
ED428 2 Protein 122/59 127/65 120/58 111/62 59 71 60 54 
ED428 3 Placebo 106/55 128/69 120/60 131/69 67 73 75 87 
                      
ED429 1 Placebo 128/68 125/68 126/62 126/62 71 69 64 55 
ED429 2 Carbohydrate 136/71 137/70 135/66 139/66 92 74 74 64 
ED429 3 Protein 122/68 110/64 128/70 127/58 62 64 66 63 
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Table 4. Subject Dietary Intake Data from 24-hour Records 
Subject # Trial Treatment Avg. Total Energy Avg. Total Protein 
Total 
Carbohydrate Total Fat 
      (kcal/day) (g/day) (g/day) (g/day) 
              
ED402 1 Protein 2152 65.829 228.44 67.49 
ED402 2 Carbohydrate 1721 57.71 211.62 75.21 
ED402 3 Placebo 2029 70.61 243.71 86.5 
              
ED404 1 Carbohydrate 2648 99.21 344.38 96.88 
ED404 2 Placebo 2486 107.6 284.46 98.26 
ED404 3 Protein 2536 95.75 318.14 94.56 
              
ED405 1 Carbohydrate 2391 76.74 326.04 90.1 
ED405 2 Placebo 2140 58.64 332.8 66.14 
ED405 3 Protein 2293 77.13 298.2 94.17 
              
ED406 1 Protein 2516 94.56 314.91 100.32 
ED406 2 Carbohydrate 1945 68.54 277.98 66.88 
ED406 3 Placebo 2118 89.97 247.6 89.09 
              
ED407 1 Carbohydrate 3568 108.39 497.5 126.41 
ED407 2 Placebo 2830 87.87 344.15 124.64 
ED407 3 Protein 2088 71.2 279.35 80.06 
              
ED409 1 Placebo 1301 83.3 219.25 13.29 
ED409 2 Carbohydrate 1793 140.01 264.36 77.24 
ED409 3 Protein 1269 59.93 220.57 21.16 
              
ED410 1 Placebo 1673 85.71 177.51 70.91 
ED410 2 Protein 1822 95.27 190.97 202.25 
ED410 3 Carbohydrate 1619 61.55 218.03 57.41 
              
ED411 1 Placebo 1724 61.3 246.95 55.5 
ED411 2 Protein 2389 50.49 205.59 63.75 
ED411 3 Carbohydrate 1228 89.81 91.29 55.46 
              
ED412 1 Carbohydrate 2223 93.55 229.1 98.59 
ED412 2 Protein 1961 72 272.06 66.76 
ED412 3 Placebo 1700 59.98 248.54 56.33 
              
ED413 1 Placebo 1364 92.97 104.48 53.74 
ED413 2 Protein 1322 66.48 160.01 48.85 
ED413 3 Carbohydrate 924 98.29 89.43 20.58 
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Table 4. Subject Dietary Intake Data from 24-hour Records (continued) 
Subject # Trial Treatment Avg. Total Energy Avg. Total Protein 
Avg. Total 
Carbohydrate 
Avg. 
Total Fat 
      (kcal/day) (g/day) (g/day) (g/day) 
ED414 1 Placebo 2021 62.96 232.87 76.86 
ED414 2 Carbohydrate 2176 96.5 234.5 71.58 
ED414 3 Protein 1421 70.94 123.69 62.64 
              
ED416 1 Protein 1673 90.23 228.19 49.42 
ED416 2 Carbohydrate 1815 94.64 276.33 39.91 
ED416 3 Placebo 1444 108.71 157.68 44.65 
              
ED418 1 Placebo 2054 95.22 210.29 96.69 
ED418 2 Carbohydrate 1735 63.49 215.65 71.55 
ED418 3 Protein 2209 97.2 252.04 88.6 
              
ED419 1 Placebo 2229 84.3 282.16 87.16 
ED419 2 Protein 1738 54.18 256.59 58.57 
ED419 3 Carbohydrate 2172 66.54 261.36 101.03 
              
ED420 1 Protein 1610 53.63 213.11 48.12 
ED420 2 Carbohydrate 2318 71.16 310.1 94.29 
ED420 3 Placebo 1829 62.82 228.12 81.26 
              
ED424 1 Placebo 2366 81.68 304.92 97 
ED424 2 Carbohydrate 2607 87.32 365.04 96.83 
ED424 3 Protein 1665 66.02 247.68 48.01 
              
ED425 1 Placebo 1581 61.16 194.4 63.54 
ED425 2 Carbohydrate 1168 44.44 150.93 130.39 
ED425 3 Protein 1228 50.68 179.23 36.62 
              
ED426 1 Placebo 1949 61.68 320.5 51.72 
ED426 2 Carbohydrate 1768 85.09 239.27 59.17 
ED426 3 Protein 2193 64.6 316.65 77.93 
              
ED427 1 Protein 2613 105.39 333.41 100.74 
ED427 2 Carbohydrate 2039 77.58 217.93 94.51 
ED427 3 Placebo 1994 95.54 174.68 103.38 
              
ED428 1 Carbohydrate 1658 67.96 200.15 68.08 
ED428 2 Protein 1944 92.04 205.11 86.16 
ED428 3 Placebo 964 48.1 116.9 34.56 
ED429 1 Placebo 2042 83.16 281.09 74.11 
ED429 2 Carbohydrate 1970 86.14 177.49 100.92 
ED429 3 Protein 1953 78.37 273.28 65.26 
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Table 5. Subject Physical Activity Data from 24-hour Records 
Subject # Trial Treatment Avg. Rest Avg. Light Exercise
Avg. Moderate 
Exercise Avg. Heavy Exercise
      (minutes/day) (minutes/day) (minutes/day) (minutes/day) 
              
ED402 1 Protein 1366.7 66.7 6.7 0.0 
ED402 2 Carbohydrate 1345.0 95.0 0.0 0.0 
ED402 3 Placebo 1388.3 31.7 20.0 0.0 
              
ED404 1 Carbohydrate 1396.7 23.3 0.0 20.0 
ED404 2 Placebo 1410.0 0.0 0.0 30.0 
ED404 3 Protein 1403.3 6.7 0.0 30.0 
              
ED405 1 Carbohydrate 1389.3 50.7 0.0 0.0 
ED405 2 Placebo 1416.3 23.7 0.0 0.0 
ED405 3 Protein 1389.0 51.0 0.0 0.0 
              
ED406 1 Protein 1156.7 243.3 26.7 13.3 
ED406 2 Carbohydrate 1100.0 100.0 240.0 0.0 
ED406 3 Placebo 1160.0 240.0 40.0 0.0 
              
ED407 1 Carbohydrate 1391.0 48.3 0.7 0.0 
ED407 2 Placebo 1375.7 61.7 2.7 0.0 
ED407 3 Protein 1409.3 30.0 0.7 0.0 
              
ED409 1 Placebo 1095.0 345.0 0.0 0.0 
ED409 2 Carbohydrate 1080.0 360.0 0.0 0.0 
ED409 3 Protein 1403.3 10.0 10.0 16.7 
              
ED410 1 Placebo 1415.0 25.0 0.0 0.0 
ED410 2 Protein 1405.0 35.0 0.0 0.0 
ED410 3 Carbohydrate 840.0 300.0 300.0 0.0 
              
ED411 1 Placebo 1353.3 55.0 31.7 0.0 
ED411 2 Protein 1176.7 216.7 46.7 0.0 
ED411 3 Carbohydrate 1338.3 65.0 36.7 0.0 
              
ED412 1 Carbohydrate 1346.7 53.3 40.0 0.0 
ED412 2 Protein 1358.3 60.0 21.7 0.0 
ED412 3 Placebo 1430.0 3.3 6.7 0.0 
              
ED413 1 Placebo 1260.0 180.0 0.0 0.0 
ED413 2 Protein 1360.0 80.0 0.0 0.0 
ED413 3 Carbohydrate 1280.0 160.0 0.0 0.0 
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Table 5. Subject Physical Activity Data from 24-hour Records (continued) 
Subject # Trial Treatment Avg. Rest Avg. Light Exercise
Avg. Moderate 
Exercise Avg. Heavy Exercise
      (minutes/day) (minutes/day) (minutes/day) (minutes/day) 
ED414 1 Placebo 1296.7 15.0 128.3 0.0 
ED414 2 Carbohydrate 1391.7 15.0 33.3 0.0 
ED414 3 Protein 1395.0 20.0 25.0 0.0 
              
ED416 1 Protein 1090.0 245.0 96.7 8.3 
ED416 2 Carbohydrate 1283.3 76.7 80.0 0.0 
ED416 3 Placebo 1111.7 198.3 121.7 8.3 
              
ED418 1 Placebo 1390.0 0.0 50.0 0.0 
ED418 2 Carbohydrate 1400.0 40.0 0.0 0.0 
ED418 3 Protein 1240.0 0.0 200.0 0.0 
              
ED419 1 Placebo 1411.7 25.0 3.3 0.0 
ED419 2 Protein 1378.3 46.7 15.0 0.0 
ED419 3 Carbohydrate 1343.3 50.0 46.7 0.0 
              
ED420 1 Protein 1366.7 73.3 0.0 0.0 
ED420 2 Carbohydrate 1328.3 101.7 10.0 0.0 
ED420 3 Placebo 1371.7 68.3 0.0 0.0 
              
ED424 1 Placebo 1340.0 40.0 60.0 0.0 
ED424 2 Carbohydrate 1305.0 135.0 0.0 0.0 
ED424 3 Protein 1425.0 15.0 0.0 0.0 
              
ED425 1 Placebo 1336.7 103.3 0.0 0.0 
ED425 2 Carbohydrate 1291.7 148.3 0.0 0.0 
ED425 3 Protein 1302.7 133.3 4.0 0.0 
              
ED426 1 Placebo 1193.3 246.7 0.0 0.0 
ED426 2 Carbohydrate 1355.0 85.0 0.0 0.0 
ED426 3 Protein 1383.3 56.7 0.0 0.0 
              
ED427 1 Protein 1390.0 50.0 0.0 0.0 
ED427 2 Carbohydrate 1400.0 40.0 0.0 0.0 
ED427 3 Placebo 1360.0 80.0 0.0 0.0 
              
ED428 1 Carbohydrate 1200.0 205.0 35.0 0.0 
ED428 2 Protein 1250.0 190.0 0.0 0.0 
ED428 3 Placebo 1235.0 205.0 0.0 0.0 
ED429 1 Placebo 1351.7 43.3 45.0 0.0 
ED429 2 Carbohydrate 1353.3 40.0 20.0 26.7 
ED429 3 Protein 1336.7 30.0 33.3 40.0 
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Table 6. Subject Biodex Isokinetic Dynamometer Muscle Strength Indices 
  
Subject #, (Trial) 
Extension 60deg 
      
Flexion 60deg 
      
 
Peak  
Torque 
Max Rep 
Tot Work 
Avg Power
  
Avg Peak 
Torque  
Peak  
Torque
Max Rep
Tot Work 
Avg Power 
  
Avg Peak 
Torque  
ED402(1)                 
Day 1 97.8 79.3 76.1 90.2 65.7 57.2 50.5 58.5
Day 2 116.6 84.5 80.8 105.6 49.4 39.6 38.9 45.7
Day 3 137.7 104 93.4 120.8 52.4 45.1 37.7 49.9
ED402(2)                 
Day 1 138.1 103.8 106.6 134.6 67.1 55 59.8 64.4
Day 2 139.1 94.3 86.3 119.2 60.9 52.5 50.8 58.4
Day 3 141.3 102.9 99.4 132.9 69.5 64.6 56.5 63.8
ED402(3)                 
Day 1 127.6 95.3 91.5 122.3 59 53.8 48.2 58.5
Day 2 126.6 100.8 91.4 117.2 63.3 66.6 49.2 59.6
Day 3 134.7 106.5 94.2 119 62.3 63.3 54.8 56.8
                  
ED404(1)                 
Day 1 160.1 114.6 117.4 145.6 108.3 93.4 7.7 97.5
Day 2 151.1 93.7 102.7 139.6 84.3 60.8 65.5 81.7
Day 3 152.1 88.2 97.4 140.2 66.2 38.6 45.5 61.1
ED404(2)                 
Day 1 143.2 113.3 110 137.4 95.7 95.5 89.3 89.7
Day 2 138.2 98.1 107 127.4 91.9 74.4 91.2 85
Day 3 139.9 77 95.9 126.8 62.8 43.6 55.6 59.9
ED404(3)                 
Day 1 159 116.3 120.1 144 92.7 87.8 89.1 89.7
Day 2 142.1 82.2 91.3 126.8 77.3 59.8 63.1 69.7
Day 3 161.6 108.3 121.1 142.3 80.8 57.7 68.2 71.1
                  
ED405(1)                 
Day 1 132.5 112.6 104.8 112.8 73.7 69.9 65.7 64.9
Day 2 130.1 111.2 101.5 113.3 77.5 64.8 54.7 66
Day 3 139.6 106.7 96.3 113.7 56 48.3 45.3 53.2
ED405(2)                 
Day 1 128.5 101.3 102.1 113.3 72.2 59.6 63.4 67.5
Day 2 135.2 106.7 96.8 110 61.9 55.2 55.5 56.2
Day 3 144.6 118.8 111.9 124.8 66.9 61.3 60.1 59.5
ED405(3)                 
Day 1 130.8 107.5 108 117.5 67.5 60 55.4 59.6
Day 2 131.5 115.1 113.8 123 65.1 56.5 57.7 60.8
Day 3 141.3 111.1 118.2 130.1 80.9 68 68.8 70.2
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Table 6. Subject Biodex Isokinetic Dynamometer Muscle Strength Indices (continued) 
  
Subject #, (Trial) 
Extension 60deg 
      
Flexion 60deg 
      
 
Peak  
Torque 
Max Rep 
Tot Work 
Avg Power
  
Avg Peak 
Torque  
Peak  
Torque
Max Rep
Tot Work 
Avg Power 
  
Avg Peak 
Torque  
ED406(1)                 
Day 1 87.2 75.4 67.4 78.4 43.9 38.5 31.4 38.5
Day 2 93.8 81.1 71.9 89.5 40 45 38.7 38.2
Day 3 79.7 75.4 65.5 77.2 32.6 35.5 60.5 31.1
ED406(2)                 
Day 1 79.1 81 63.9 72.5 46.7 56.7 43 42.1
Day 2 66.4 60.1 53.4 63.6 34.2 38.4 60.9 33
Day 3 62.7 56.3 47.4 57.1 33.4 33.7 28.5 30.2
ED406(3)                 
Day 1 54.4 56.2 45.2 50.4 31.9 38.3 28.8 28.2
Day 2 52.4 54.3 41.3 46.6 29.2 32.6 25.5 28
Day 3 52 46.7 39.8 45.2 31 32.2 27.8 28.8
                  
ED407(1)                 
Day 1 118.5 96.8 73.3 90.3 56.4 67.2 54.3 54
Day 2 101.8 92.9 76.1 94.7 52 54.5 44.4 46.9
Day 3 140.6 150.8 99.8 130.9 62 72.2 48.8 56.8
ED407(2)                 
Day 1 119.9 106.5 81.9 102.2 85.9 100.4 81 79.3
Day 2 121.5 107.3 85.8 112.2 74.3 85.7 65.8 68.6
Day 3 138.8 127.5 102.3 126.6 73.1 90.2 67.7 68.1
ED407(3)                 
Day 1 139.3 124.7 98.6 127 74.2 91.9 71.5 68.8
Day 2 134.3 117.2 91.1 124.6 76 93.9 75.3 71.6
Day 3 152.9 128.1 9.3 131.6 95.6 121 94.8 87.8
                  
ED409(1)                 
Day 1 151.6 97.7 116.6 130.2 75.8 59.3 69.8 70.1
Day 2 131.2 94.3 93.6 109.7 66.2 59.2 54.3 59.1
Day 3 119.5 101 100.9 112.8 64.1 57.1 60.4 57.6
ED409(2)                 
Day 1 138.7 111.2 123.4 134.5 76.7 69 76.1 71.2
Day 2 139.7 110.2 114 125.4 70.9 60.2 74.5 65.1
Day 3 147.6 102 128.3 136.5 80 57.9 74.3 72.8
ED409(3)                 
Day 1 133.8 94.3 99.8 104.6 74.7 50.4 66.1 64.8
Day 2 148.7 109.7 106.2 115.5 77.9 63 67.9 70.3
Day 3 135.7 96.9 109.1 118.2 80 57.6 73.8 74.9
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Table 6. Subject Biodex Isokinetic Dynamometer Muscle Strength Indices (continued) 
  
Subject #, (Trial) 
Extension 60deg 
      
Flexion 60deg 
      
 
Peak  
Torque 
Max Rep 
Tot Work 
Avg Power
  
Avg Peak 
Torque  
Peak  
Torque
Max Rep
Tot Work 
Avg Power 
  
Avg Peak 
Torque  
ED410(1)                 
Day 1 129.1 141.3 91.6 114.1 72.4 104.8 71.2 69.3
Day 2 122 108.8 88.3 110.9 75.8 89 66.3 68.8
Day 3 122.7 114.6 87.1 113.5 69.9 85.6 56 61.1
ED410(2)                 
Day 1 122.9 110.1 85.7 115.4 69.8 91.1 70.7 66.8
Day 2 127.5 113.4 90.2 122 66.4 79.9 60.7 58.3
Day 3 127.3 112.8 95 117.8 64.1 76.8 63.8 58.4
ED410(3)                 
Day 1 117.9 100.7 88.2 106.5 80.1 86.2 71.5 68.7
Day 2 129.1 109.8 103.4 115.8 69.6 62.5 66.3 65.8
Day 3 145.5 136 114.2 129.6 79.6 97.5 85.3 78.1
                  
ED411(1)                 
Day 1 119.9 98.5 115.3 116.1 79.6 75.1 85.7 77.2
Day 2 113.4 85.2 105 108.3 66.9 54.2 53.6 63.5
Day 3 131.5 106.3 120.7 124.4 62.3 55.9 63 60.2
ED411(2)                 
Day 1 130.7 101.3 109.5 119.9 90.9 86.3 94.5 88.9
Day 2 127.4 87 97 114.7 86.8 71.3 80.7 78.4
Day 3 118.9 86.5 97.7 106.3 86.3 75.5 86.2 84.2
ED411(3)                 
Day 1 144.8 103.9 116.5 131.3 96.5 89.8 98.5 92.2
Day 2 143 117.4 125.3 131.6 84.2 3.3 78.2 77.8
Day 3 114.2 81.8 98.8 109.4 77.8 64.5 74.6 74.7
                  
ED412(1)                 
Day 1 118.5 101.4 96.5 104.4 82.3 85.1 80 78.7
Day 2 127.4 113.9 100.7 115.5 78.5 92.2 75.6 75.9
Day 3 156.2 144.5 124.5 143.7 82 96.3 79.6 80.5
ED412(2)                 
Day 1 147 147.7 111 134.2 88.2 112 69.5 78.2
Day 2 154.6 137.8 117.9 142.4 88.6 94.2 80.6 85.4
Day 3 140.3 130.1 107.1 131.1 84.9 97.7 75.8 79.6
ED412(3)                 
Day 1 133.3 126.9 103.9 122.7 87.9 104.8 83.6 84
Day 2 163.2 147.6 116.3 146.5 95.4 108.1 87 92
Day 3 142.1 127.9 102.6 132.8 87.9 97.6 77.7 85.4
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Table 6. Subject Biodex Isokinetic Dynamometer Muscle Strength Indices (continued) 
  
Subject #, (Trial) 
Extension 60deg 
      
Flexion 60deg 
      
 
Peak  
Torque 
Max Rep 
Tot Work 
Avg Power
  
Avg Peak 
Torque  
Peak  
Torque
Max Rep
Tot Work 
Avg Power 
  
Avg Peak 
Torque  
ED413(1)                 
Day 1 120.8 119.3 99.1 105.2 65.3 67.8 60.7 58.2
Day 2 90.9 74.5 74.9 82.1 50.2 43.6 39.1 45.3
Day 3 107.6 77.9 73 91.7 58.1 45.6 39.8 50.7
ED413(2)                 
Day 1 106 84.2 82.9 95 64.6 55.9 57.9 58.7
Day 2 111.3 83.3 88 100.2 66.8 60.2 63.3 62.4
Day 3 107.2 89.5 90.9 100.3 70.7 68.6 67.7 65.3
ED413(3)                 
Day 1 111.5 83.1 82.4 96.4 66.1 62 59.9 62.7
Day 2 113.4 83.3 87.3 103.5 72.2 60 63.6 65.8
Day 3 130 120.8 110.6 117.4 80.3 78.4 70.7 77.2
                  
ED414(1)                 
Day 1 168.6 126.5 124.9 151.7 97.3 111.1 95.4 89.7
Day 2 164.3 128 123.9 150.6 91.8 100.6 91 86
Day 3 166.9 138.4 123.7 148.7 94.7 102.8 91.1 91.1
ED414(2)                 
Day 1 173 151.9 145.8 162.2 109.9 128 107.6 96.7
Day 2 158.8 134.6 129.2 151.9 90.6 99.6 92 85.3
Day 3 164.3 134.6 127.8 155.1 95.5 104.7 98.2 88.6
ED414(3)                 
Day 1 172.1 139.1 128.6 163.2 98.3 99.1 90.1 90.7
Day 2 149.5 113.5 103.9 141.3 92 88.3 78.5 84.3
Day 3 158 116.6 115.6 144.7 93.3 92.2 84.6 84.1
                  
ED416(1)                 
Day 1 132.8 131.1 116.3 126.2 89.6 96.8 85.1 87.5
Day 2 159.2 135.9 124.5 147 101.8 104.2 92.5 96.8
Day 3 156.7 140 128 144.3 103.7 104.1 77.4 89
ED416(2)                 
Day 1 157.4 145.1 140.4 144.5 100.8 96.6 93.5 93.8
Day 2 160.6 146.1 135.3 153.6 102.6 95.6 81.3 95.2
Day 3 157.8 127.8 129.8 144.2 91.9 73.9 74.3 89
ED416(3)                 
Day 1 172.9 143.4 134.9 153.5 107.7 101.7 95.5 103.9
Day 2 169.1 138.3 128.5 156.6 99.9 84.8 79.1 91.7
Day 3 157.7 131 119.5 145.6 93.3 89.5 79.7 87.2
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Table 6. Subject Biodex Isokinetic Dynamometer Muscle Strength Indices (continued) 
  
Subject #, (Trial) 
Extension 60deg 
      
Flexion 60deg 
      
 
Peak  
Torque 
Max Rep 
Tot Work 
Avg Power
  
Avg Peak 
Torque  
Peak  
Torque
Max Rep
Tot Work 
Avg Power 
  
Avg Peak 
Torque  
ED418(1)                 
Day 1 122.8 122.3 89.9 110.6 76 101 77.5 73.8
Day 2 99.1 88.8 72.5 89.7 53 63.6 50.7 51.9
Day 3 124 126.4 99.9 115.7 55.2 69.6 54.1 50.9
ED418(2)                 
Day 1 108.7 97.9 50.4 96.1 64.6 76.5 62 59.8
Day 2 108.7 104 80.5 101.7 61.5 75.2 57.5 59.6
Day 3 116.2 117.4 85.7 109.8 65.6 89.6 63.3 61.7
ED418(3)                 
Day 1 137.1 135.6 95.4 123.1 76.8 107.4 72.3 68.8
Day 2 122 118.6 93.7 116.4 75.1 98.1 72.7 70.1
Day 3 113 106.8 86.1 107.7 75.2 99.5 75.2 74.2
                  
ED419(1)                 
Day 1 97.9 54.3 69.3 85.7 54.4 35 43.7 48.5
Day 2 68.8 38 39.3 48.6 36.4 19.6 13.9 27.3
Day 3 103.2 62.8 67.8 81.4 48.8 30.7 38.3 43.1
ED419(2)                 
Day 1 91.6 64.1 70.9 81.3 49.7 40.9 41.6 42.1
Day 2 75.2 56.4 44.3 57.6 46.4 38.2 36.9 38.8
Day 3 95.8 71.9 68.4 77.8 52.5 43.8 49.4 48.5
ED419(3)                 
Day 1 120 96.1 91.2 93.8 62.7 62.4 61.9 58.1
Day 2 118.4 93.7 96.4 104.1 69.5 58.6 64.6 62.7
Day 3 117.8 83 78 100.5 61.2 52.2 52.3 55.2
                  
ED420(1)                 
Day 1 108.5 99 77.1 90.9 81.2 81.4 78.7 78.3
Day 2 90.4 74.5 67.7 77.6 50.9 81.2 45.1 46.8
Day 3 96.2 71.4 69.2 79.8 44.9 34.4 37.8 39.7
ED420(2)                 
Day 1 106.1 92.5 86 98.4 77.8 82.4 71.2 71
Day 2 132.8 99.4 86.2 103.2 82.8 81.7 75.9 72.1
Day 3 142.8 123.6 103.5 120.6 93 100 85 83.4
ED420(3)                 
Day 1 124.5 85.3 85.1 101.2 98.7 95.5 81.4 85.6
Day 2 153.7 121 106.7 123.7 78.4 84.8 80.5 74.5
Day 3 164.6 138.9 122 136.3 93.5 98.4 95.6 87.7
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Table 6. Subject Biodex Isokinetic Dynamometer Muscle Strength Indices (continued) 
  
Subject #, (Trial) 
Extension 60deg 
      
Flexion 60deg 
      
 
Peak  
Torque 
Max Rep 
Tot Work 
Avg Power
  
Avg Peak 
Torque  
Peak  
Torque
Max Rep
Tot Work 
Avg Power 
  
Avg Peak 
Torque  
ED424(1)                 
Day 1 142.6 90.7 102.9 128.4 78.3 62 49.1 71.3
Day 2 128.2 93.5 94.6 108.5 74.8 59.9 63.1 70.2
Day 3 124.3 96.3 96.8 108.8 58.8 46.1 48.2 54.3
ED424(2)                 
Day 1 109.4 84.8 78.4 89.9 71.9 61.1 52.9 71.2
Day 2 137.8 101.9 112.1 118.8 76.3 60.1 68.6 71.7
Day 3 154.6 116.9 116.1 129.6 75.4 67.1 70.1 69.1
ED424(3)                 
Day 1 113.6 89.7 94.8 100.2 84.3 68 75.3 79.9
Day 2 142 113.2 111.3 124.1 74.3 64.7 65.2 70
Day 3 108.8 87.2 74.5 92.3 64.7 53.8 50.8 59.7
                  
ED425(1)                 
Day 1 73.1 60 51.7 64 63.3 66.7 49.5 58.6
Day 2 109.4 103.9 75.8 97.7 52.3 53.9 39.5 46.7
Day 3 120.2 112.6 83.3 108.4 43.8 42.3 31.5 39.1
ED425(2)                 
Day 1 122.3 110 88.2 118.8 56.5 62.4 47.3 52.4
Day 2 117.9 102.1 79.9 105.7 47.9 45.7 37.5 42.4
Day 3 128.6 111.8 84.4 114 53 52.1 42 51.6
ED425(3)                 
Day 1 119 107.6 85 114.3 70.3 72.4 58.5 62.5
Day 2 126.6 109 86 111.2 62.9 62 53.8 59.4
Day 3 122.5 104.3 82.1 103.7 65.1 61.6 46.9 54.2
                  
ED424(1)                 
Day 1 160.2 121.8 96.4 134.2 76.7 94.2 69.3 70.3
Day 2 139.1 107.9 93.5 120.1 66.8 76.9 58.7 62.4
Day 3 130.8 112.8 89 116.7 60 71.2 57.9 56.6
ED426(2)                 
Day 1 125.8 98.8 83 114.7 68.5 78.4 61.4 58.4
Day 2 123.7 114.3 97.4 114.6 62.7 70.8 59.9 59.7
Day 3 129.6 124.7 102.3 124.4 65.5 86.5 65.3 60.3
ED426(3)                 
Day 1 136.7 130.1 101.6 127.1 68 97.9 72.2 65.7
Day 2 139.9 132.1 96.1 122.4 71.4 99.4 65.3 59.3
Day 3 144.6 135.5 16.7 135.9 77.3 102 72.7 69.2
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Table 6. Subject Biodex Isokinetic Dynamometer Muscle Strength Indices (continued) 
  
Subject #, (Trial) 
Extension 60deg 
      
Flexion 60deg 
      
 
Peak  
Torque 
Max Rep 
Tot Work 
Avg Power
  
Avg Peak 
Torque  
Peak  
Torque
Max Rep
Tot Work 
Avg Power 
  
Avg Peak 
Torque  
ED427(1)                 
Day 1 148.5 124.7 102.7 132.5 73.5 77 56.1 60.2
Day 2 164.2 132.9 98.1 130.3 99.5 110.8 74.5 77.4
Day 3 190.1 157.7 124.9 160.3 103 112.9 94.1 94.4
ED427(2)                 
Day 1 160.6 147.8 120.4 154.6 90.7 96.1 83.3 85.2
Day 2 174.9 141.5 121.2 156.7 104.9 109.8 82.5 86.4
Day 3 174.6 160.6 130.4 163.1 103.2 121.7 105.4 97.7
ED427(3)                 
Day 1 136.4 130.3 104 127.2 93.1 95.2 77.2 82.7
Day 2 166.1 136.2 120 150.5 89.4 92.4 79.3 82.3
Day 3 187 180.1 146.6 146.7 162.6 263.9 104.2 109.8
                  
ED428(1)                 
Day 1 132.7 132.4 104.8 126.1 107.6 130.1 90.1 92.4
Day 2 142.2 138.9 115.5 137.7 90.5 107.6 84.6 85.2
Day 3 148.4 135.4 112.3 130.2 68.2 71.6 63.9 62
ED428(2)                 
Day 1 130 132.3 98.5 114.4 77.6 94 73.9 70.3
Day 2 137 129 101.1 118.1 81.7 99.6 76.7 74.2
Day 3 165.5 163 123.2 146.5 89.9 115.9 89.7 86.1
ED428(3)                 
Day 1 144.1 127.4 95.2 118 69.7 83 63 63.6
Day 2 156.6 135.4 105.4 129.3 87 104.5 71.3 72.4
Day 3 150.8 135.3 97.2 126.5 81.3 105.9 78 73.3
                  
ED429(1)                 
Day 1 114.8 105.9 80.6 101.3 76.7 86.4 68.3 74.2
Day 2 103.1 85 79.9 95.8 69.9 66.8 61.2 68.4
Day 3 101.2 90.6 76.3 91.4 60.6 63.1 50.9 56.6
ED429(2)                 
Day 1 107.9 88.4 86 100.2 71.8 60 62.6 68
Day 2 112.1 100.5 95.2 105.1 74.6 67.7 56.5 67.3
Day 3 115.9 112.7 95.6 110.6 73.9 84.1 68.1 71.2
ED429(3)                 
Day 1 117.4 94.7 89.3 112.3 72.7 75.7 68.2 68.7
Day 2 123.6 104.8 96.5 113.6 81 77.8 73.2 76
Day 3 123.5 105.2 101.2 113.1 75.2 76.7 73 71.6
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APPENDIX E:  ADDITIONAL TABLES AND FIGURES 
 
Table 1. Descriptive Statistics of Subjects at Baseline:  Level of Exertion (0-10 cm scale) 
and Physical Activity According to Treatment 
 
1ANOVA indicated that there were no significant differences among treatment groups. 
2 Physical activity based on 24-hour records 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Treatment Group   
 Potential Confounding Factors Placebo Protein Carbohydrate  
Comparison 
Among 
Groups1 
  Mean ± SD Mean ± SD Mean ± SD  p-value 
Perceived Level of Exertion (0-10 cm):      
    First eccentric set of contractions 8.2 + 1.6 8.0 + 1.4 7.8 + 1.5  0.68 
    Last eccentric set of contractions 8.6 + 0.9 8.8 + 0.6 8.7 + 0.8  0.66 
Recorded Physical Activity (min/day)2:      
    Rest 1318 + 102 1334 + 96 1293 + 138  0.52 
    Light 96 + 99 78 + 79 104 + 90  0.62 
    Moderate 24 + 39 23 + 47 40 + 80  0.57 
    Heavy 2 + 7 5 + 11 2 + 7  0.40 
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Figure 1. Effect of Day on CPK Activity (U/L) During All Trials Combined 
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Day:   1  2   3 
Maximum:  479  1172   2241 
Minimum:  40  86   57 
 
Median values are reported since the data were not normally distributed. Different letters 
indicate a significant (p≤0.0001) difference from day to day. 
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Figure 2. Effect of Day on Perceived Muscle Soreness (0-10 cm) During All Trials 
Combined 
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Day:   1  2   3 
Maximum:  4.6  9.3   9.9 
Minimum:  0.0  0.8   0.0 
 
Median values are reported since the data were not normally distributed. Different letters 
indicate a significant (p≤0.0001) difference from day to day. 
 
 
 
 
 
 
 
 
 
 
 
 
b 
a 
b 
  
79
Figure 3. Serum CPK Activity (U/L) According to Trial 
 
Different letters indicate significant (p=0.039) difference from trial to trial. 
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Figure 4. Perceived Muscle Soreness (0-10 cm) According to Trial 
 
 
Different letters indicate significant (p≤0.0002) difference from trial to trial. 
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Table 2. Descriptive Statistics of Subjects:  CPK (U/L) and Muscle Soreness (0-10 scale) 
at Each Time Point, According to Treatment 
  Median Minima Maxima 
  Placebo PRO CHO Placebo PRO CHO Placebo PRO CHO
CPK (0 hr) 150 138 131 40 46 53 479 463 290 
CPK (0.5 hr) 137 143 128 42 48 40 470 478 290 
CPK (24 hr) 251 229 228 103 86 111 924 836 1172 
CPK (48 hr) 214 160 194 92 57 93 2241 572 844 
Muscle Soreness (0 hr) 0.4 1.0 1.1 0.0 0.0 0.0 4.6 2.3 2.7 
Muscle Soreness (0.5 hr) 6.0 5.3 5.9 0.5 0.3 0.7 10.0 9.0 8.6 
Muscle Soreness (24 hr) 3.9 2.9 3.1 1.2 0.9 0.8 8.0 7.0 9.3 
Muscle Soreness (24.5 hr) 5.5 4.0 4.5 1.1 0.4 0.7 8.7 8.6 9.3 
Muscle Soreness (48 hr) 4.4 3.0 3.4 1.0 0.0 1.7 8.7 9.9 8.7 
Muscle Soreness (48.5 hr) 4.9 4.8 4.1 1.0 0.5 1.6 9.3 9.6 7.6 
 
Includes medians, minimums, and maximums. Median (minima, maxima) values are reported 
because CPK and muscle soreness data were not normally distributed. 
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Table 3. Effect1 of Day, Trial, and Treatment for Muscle Soreness Measures 
  Day 
Overall 
Day 1 
versus 2 
Day 1 
versus 3
Day 2 
versus 3
Trial 
Overall
Trial 1 
versus 2 
Trial 1 
versus 3 
Trial 2 
versus 3 
Treatment
Overall 
Treatment
A versus B
Treatment
A versus C
Treatment
B versus C
Extension Peak 
Torque (ft-lbs) 
0.018 0.65 0.008 0.028 0.001 0.30 0.0004 0.015 0.25 – – – 
Extension Max Rep 
Total Work (ft-lbs) 
0.018 0.43 0.047 0.006 0.017 0.20 0.0043 0.14 0.31 – – – 
Extension Average 
Power (Watts) 
0.75 – – – 0.17 – – – 0.019 0.31 0.081 0.005 
Extension Average 
Peak Torque (ft-lbs) 
0.031 0.93 0.020 0.025 0.003 0.085 0.0007 0.11 0.070 – – – 
Flexion Peak  
Torque (ft-lbs) 
0.031 0.014 0.039 0.70 <0.0001 0.020 <0.0001 0.018 0.56 – – – 
Flexion Max Rep 
Total Work (ft-lbs) 
0.034 0.010 0.24 0.15 0.009 0.043 0.003 0.37 0.54 – – – 
Flexion Average 
Power (Watts) 
0.12 – – – <0.0001 <0.0001 <0.0001 0.45 0.95 – – – 
Flexion Average 
Peak Torque (ft-lbs) 
0.007 0.003 0.012 0.66 <0.0001 0.008 <0.0001 0.024 0.29 – – – 
 
1 ANOVA for overall effect of day, trial, and treatment 
“–” indicated that the follow-up comparisons were not applicable 
Treatments:  A=placebo, B=protein, C=carbohydrate 
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